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Abstract 
 
 In the heart, electrical signaling is responsible for its rhythmicity and is necessary 
to initiate muscle contraction.  The net electrical activity in a cardiac myocyte during a 
contraction cycle is observed as the action potential (AP), which describes a change in 
membrane potential as a function of time.  In ventricular cardiac myocytes, voltage-gated 
sodium channels (Nav) and voltage-gated potassium channels (Kv) play antagonistic roles 
in shaping the AP with the former initiating membrane depolarization and the latter 
repolarizing it.  Functional changes in the primary cardiac Nav isoform, Nav 1.5, or any 
one of the many Kv isoforms expressed in the ventricle, as evidenced by those 
characterized in various congenital and/or acquired etiologies, can lead to severe cardiac 
pathologies.  Nav and Kv are large transmembrane proteins that can be extensively post-
translationally modified through processes that include glycosylation.  The sequential 
glycosylation process typically ends with negatively charged sialic acid residues added 
through trans-Golgi sialyltransferase activity.  Sialyltransferases belong to a much larger 
group of glycogene products that number in the hundreds and are responsible for creating 
a complex and variable glycan profile (glycome) unique to different cell types and 
tissues.  Sialic acids impact Nav and Kv function likely by contributing to the extracellular 
surface potential and thereby causing channels to gate following smaller depolarizations.  
Additionally, developmentally regulated sialylation contributes to cardiac myocyte 
excitability in the neonatal mouse atria.  However, little is understood concerning how 
xi 
 
the glycosylation machinery (glycogene products) influences cell and tissue electrical 
signaling.   
 The sialytransferase β-galactoside α-2,3-sialyltransferase 4 (ST3Gal4) adds sialic 
acids to galactose residues of N- and O-linked glycans through α-2,3-linkgages.  
ST3Gal4 is uniformly expressed throughout the chambers and developmental stages of 
the heart and therefore is likely a useful target to question whether and how glycosylation 
impacts these events.  Additionally, diseases of glycosylation often cause symptoms that 
are consistent with changes in excitability that include arrhythmias and seizures.  
Congenital disorders of glycosylation lead to variably reduced glycoprotein and 
glycolipid glycosylation.  However, because sialic acids are typically the terminal 
residues added to glycan structures, disease-related reduced glycosylation often leads to 
fewer sialic acids being attached.  In addition, Chagas disease, which results in 
pathological changes in cardiac electrical function, may reduce sialic acids directly.  
Because of this, the ST3Gal4
-/-
 strain was also used to investigate the role of 
glycosylation in the pathological cardiac electrical remodeling often associated with these 
diseases.  The methodologies included cellular, tissue and whole-animal 
electrophysiology as well as biochemical assays.  The data indicate that deletion of 
ST3Gal4 significantly affects Nav sialylation and gating with no change in maximum 
current density or protein expression.  ST3Gal4 deletion also depolarizes the activation 
gating of both voltage-dependent kinetic components of repolarization found in the 
mouse ventricle: Ito and IKslow; however unlike the effect on INa, ST3Gal4 gene deletion 
causes a reduction in the peak IK density.  Protein expression of the putative Kv isoforms 
responsible for Ito and IKslow was variably affected by ST3Gal4 gene deletion with Kv1.5 
xii 
 
and Kv4.2 demonstrating no differences in protein densities.  Contrastingly, a small but 
significant reduction in Kv2.1 protein from ST3Gal4
-/-
 ventricular tissue was observed.  In 
addition to effects on Nav and Kv activity, ST3Gal4 expression is necessary for normal 
cellular electrical signaling as demonstrated by a reduction in cellular refractory period 
and alterations in AP waveforms that include a slowing of cellular conduction and an 
extension of AP duration in ventricular myocytes from ST3Gal4
-/-
 mice.  Concurrent with 
aberrant excitability at the cellular level, the ST3Gal4
-/-
 left ventricular epicardium 
demonstrated a reduced refractory period and was more susceptible to arrhythmias as 
observed through optical mapping studies.  Additionally, ECGs of ambulatory ST3Gal4
-/-
 
mice demonstrated that deletion of the gene causes modest aberrant conduction under 
basal conditions and, in preliminary studies, appears to increase susceptibility to 
arrhythmias following a cardiac challenge, in the form of a low dosage of the β-
adrenergic agonist isoproterenol, suggesting a reduction in repolarization reserve in 
ST3Gal4 hearts.  Based on the data reported here, it is apparent that relatively minor 
perturbations in the cardiac glycome cause significant changes in cardiac electrical 
signaling.  These data highlight the role of glycosylation in normal physiology and 
underscore it as an important mediator in diseases where it may be altered. 
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Chapter 1 
Introduction 
 
1.1. A historical perspective on electrophysiology and the role of voltage-gated ion 
channels in excitability 
Electrical signaling is a vital biological function that developed concurrently with 
the evolution of increasingly sophisticated organisms and presumably facilitated that 
evolution[1-4].  Electrical signaling not only provides a rapid means of intra- and 
extracellular communication vital to the integration of different organs and physiological 
systems but also provides a driving force and rhythmicity for many cellular functions.  
Cardiac and skeletal muscle and neuronal activities are most often associated with 
electrical signaling but other processes such as secretion and immune responses also 
depend on the passive and active movement of ions across cellular membranes. The 
modern age of electrophysiology began in the 1940s and 50s when A.L. Hodgkin, A.F. 
Huxley, B. Katz, and others performed their famous experiments[5-15].  Utilizing the 
axons of squid, two phenomena quintessential to the principles of electrical signaling 
were described: cells are selectively permeable to ionic species and ionic flux is mediated 
through voltage changes.  Through electrophysiological experiments, Hodgkin and 
Huxley as well as other groups that followed, were able to describe many of the 
biophysical properties of the unknown ionic transporters.  What the groups were 
observing primarily was the action of a family of proteins classified as voltage-gated ion 
channels (VGIC).  The ability of a VGIC to sense a change in voltage and gate open to 
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create a permeation pathway for specific ions, was first described by Hodgkin and 
Huxley during experiments observing Na
+
 currents where they predicted that the increase 
in Na
+
 conductance depended on the movement of charged particles in response to a 
change in voltage[10].  Later, this was observed directly by several groups as a relatively 
small electrical current that preceded the ionic conductance through the channel and was 
termed, “gating charge”[16-19].  It was discovered that the nature of this gating current 
involved the movement of positively charged arginine and lysine residues in a specific 
region of the channels, which is common among VGIC types[20, 21].  There are four 
families of VGICs that are classified by the ion they are most specific for in a 
physiological setting and include voltage-gated Ca
2+
 (Cav), voltage-gated Na
+ 
(Nav), 
voltage-gated K
+ 
(Kv) and voltage-gated Cl
- 
(ClC) channels.  Typically, Nav and Kv play 
oppositional roles in electrical excitability with the former “activating” or depolarizing 
the cell and the latter “deactivating” or repolarizing the cell.  Nav and Kv are structurally 
homologous sharing a four-fold symmetry that consists of either domains, in the case of 
Nav, or subunits, in the case of Kv.  The difference originates from the organization of the 
protein: Nav are one gene product while Kv are formed from multiple gene products 
assembling in a homo- or heterotetrameric manner[22, 23].  Each subunit/domain 
consists of 6 transmembrane segments and it is within these segments where the arginine 
and lysine residues, which generate gating current, reside (Fig. 1.1).  Specifically, the 
fourth segment (S4) contains arginines and lysines every 3 to 4 residues with arginine 
being the predominate amino acid found[20].   
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Figure 1.1: Structures of voltage-gated Na
+
 and K
+
 channels.  A, Structure of a typical 
Nav.  B, Structure of a typical Kv.  For both note the four-fold symmetry which differs in 
that Nav are one polypeptide and Kv are four individual subunits.  Figure modified from 
Boron and Boulpaep Medical Physiology[24] reprinted with permission. 
 
There are 3 prevailing theories that describe voltage-sensing: the paddle, the helical 
screw and the transporter model[20]; however, the overarching theme of the 3 models is 
that the S4 region(s) interacts electrostatically with the local electric field across the cell 
membrane causing segments 1 through 4 to change conformation.  This movement, in 
turn, affects the conformation of segments 5 and 6 (the pore), which leads to voltage 
dependent activity of the channel.  The resting membrane potential is the source of 
potential energy for VGIC activity and is created by the actions of various ionic 
transporters and exchangers that create a charge gradient across the membranes of 
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excitable cells.  It is through changes in the membrane potential and electrostatic 
interactions that VGICs move in and out 3 distinct conformations (gating): open, inactive 
and closed.  The rates and voltages at which these events occur differ considerably 
between VGIC types.  There are 9 mammalian Nav isoforms that all possess unique 
biophysical properties and expression patterns[25].  The differential expression and 
activity of these isoforms have important physiological roles.  For example, Nav1.9 is 
expressed in nociceptive neurons[26].  They activate at relatively hyperpolarized 
potentials and inactivate slowly allowing for persistent Na
+
 current.  It is thought that 
Nav1.9 contributes little to depolarization but rather to setting the threshold for activation 
and the resting membrane potential[27].  These features play a vital role in 
nociception[26].  Contrastingly, Nav1.4 is primarily expressed in skeletal muscle where 
cell depolarization must occur quickly and be flexible to repeated stimulation.  
Concurrent with this, Nav1.4 activates rapidly, conducts a relatively large amount of Na
+
 
and channel availability is depolarized[25, 28].  The channel also inactivates and recovers 
from inactivation rapidly compared to other Nav isoforms.  Kv channels are represented by 
approximately 60 different isoforms that demonstrate even more variability in function 
and expression than Nav[23].  Diverse tissue and cell types have developed an array of 
VGIC types to meet physiological demand. 
 
1.2. The role of electrical signaling the heart 
 The ability of the heart to pump blood throughout the body is dependent upon the 
synchronous contraction of individual cardiomyocytes.  In order to drive the machinery 
of contraction, the cytosolic Ca
2+ 
concentration must increase.  Ca
2+ 
influx into the 
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cytosol occurs via 2 pathways: a voltage sensitive extracellular pathway and a calcium 
dependent intracellular pathway.  The driving force for the required increase in cytosolic 
Ca
2+ 
is derived from ionic flux across the cell membrane, which contributes to excitation-
contraction (E-C) coupling.  Upon activation of a cardiomyocyte, the membrane 
depolarizes beginning a dynamic process that ultimately results in the influx of 
extracellular Ca
2+ 
and the Ca
2+
-dependent release from intracellular stores.  Upon 
completion of contraction, the membrane is restored to the resting potential.  In addition 
to initiating contraction by increasing intracellular Ca
2+
, myocyte electrical signaling is 
also necessary to maintain cardiac conduction and rhythmicity.  A cardiac myocyte action 
potential (AP)[29] varies among areas of the heart[29, 30] and among species[31] but 
generally consists of 5 phases (Fig. 1.2).  In atrial and ventricular myocytes inward 
sodium current (INa), through Nav, causes the rapid and unstoppable depolarization of the 
membrane or phase 0.  While a number of Nav isoforms at the transcript or protein level 
were observed[32, 33], Nav1.5 is the predominate isoform[34, 35].  The structure and 
distribution of Nav1.5 is generally conserved across different species and there is 
evidence that there are regional differences in the expression patterns of the channel 
throughout the heart[36, 37].  Nav1.5 inactivates rapidly, on the order of a few 
milliseconds (ms), which contributes to phase 1 of the AP.  Interestingly the position 
along the voltage axis of the voltage-dependent inactivation curve of Nav1.5 occurs in 
such a place that renders few channels available at a normal myocyte resting potential.  In 
spite of this depolarization is robust, which suggests redundancy.   
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Figure 1.2: Action potentials in human and mouse ventricular myocytes.  
Representation of human (A) and mouse (B) ventricular myocyte APs and ionic 
correlates.  From Nerbonne[47] reprinted with permission. 
 
What is likely as important as activation of the channels to depolarize the membrane to 
cardiac rhythm isthe rate at which the channels recover from fast inactivation.  Recovery 
from fast inactivation is timed in such a way that, in healthy cardiac tissue, does not allow 
for deviations in the normal conduction path.  As phase 0 ends and phase 1 begins, Cav 
activate and further depolarize the membrane.  The L type Ca
2+ 
channel, or Cav1.2, is the 
predominate Cav isoform in adult ventricular myocytes[38].  Cav1.2 inactivates slowly 
and Ca
2+
 influx persists through phases 1 through 3 of the AP.  Cav activity is tightly 
coupled to sarcoplasmic Ca
2+ 
channels, or Ryanodine receptors (RyRs), which in the 
heart, principally consists of the isoform RyR2[39].  E-C coupling requires Ca
2+ 
influx 
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through Cav1.2 that leads to calcium mediated calcium release from sarcoplasmic stores 
via RyR2[40, 41].   
Phase 1 also denotes the activation of Kv, whose activities persist through phase 4 
of the AP.  Kv exhibit vast diversity throughout regions of the heart and across species, 
with each isoform possessing unique biophysical properties[30].  Kv play a vital role in 
shaping the AP; as written by Bertil Hille: "like the stops on an organ, the diversity of 
available (Kv) channels is used to give timbre to the functions played by excitable 
cells[23]."  What Hille is referring to is that the shape and length of the AP is primarily 
determined by the activity of each unique Kv isoform and the diverse distribution of Kv 
isoforms has important physiological ramifications.  For example, in large mammals, 
such as humans, ventricular repolarization occurs through two main Kv isoforms: Kv11.1 
and Kv7.1 both of which contribute to IKr and IKs current types respectively during phases 
2 through 3 of the AP[30, 42].  The activities of these 2 isoforms are characterized by 
long sustained K
+
 efflux allowing the cell to remain depolarized for relatively long 
periods of time.  The long depolarized state of the cell maintains persistent intracellular 
Ca
2+ 
throughout a cycle of contraction.  It is this long duration of intracellular Ca
2+
 that 
allows for the robust contractive force necessary in the ventricles of large mammals.  
Conversely, the mouse ventricle repolarizes rapidly, which is likely due to a smaller 
requirement of contractile force and occurs primarily through the activity of 4 isoforms: 
Kv4.2/Kv4.3, Kv1.5 and Kv2.1[43].  Kv4.3 is also found in the human ventricle but is only 
responsible for a small fraction of repolarization during phase 1 or the "notch," which 
may also consists of a Ca
2+ 
dependent outward Cl
- 
 current[42, 44].  In the mouse 
ventricle, phases 2 and 3 are less differentiated than in larger mammals and are generally 
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delineated as kinetic components: the rapidly inactivating Ito, which is likely conducted 
through the heterotetrameric assembly of Kv4.2/4.3, and the slowly inactivating 
components: IKslow1, and IKslow2 which are likely conducted through Kv1.5 and Kv2.1 
respectively[43].  The human atria are repolarized primarily through the action of 
Kv1.5[45, 46].  Mouse atrial repolarization is well conserved with the ventricle in terms 
of the Kv isoforms expressed; however, septal myocytes appear to also express the Kv 
isoform responsible for the slowly inactivating transient outward current (Ito,s): Kv1.4 and 
repolarization is generally longer lasting in these cells[43].  Kv1.4 is expressed in the 
human ventricle and is active during phases 1 and 2[30, 47].  Figure 1.2 details the major 
differences in AP waveforms between human and mouse ventricular myocytes as well as 
the contributing current types.  In addition to differences in Kv isoforms between species 
and regions of the heart, individual isoforms can be transmurally expressed.  For example 
Kv4.3 is more highly expressed in the epicardium compared to the endocardium and the 
subsequent current density is higher in that region[48].  The transmural gradient allows 
for a physiologic dispersion of repolarization throughout the myocardium[49].  Phase 4 
occurs through a wide-range of ion channels and transporters that function to set the 
resting membrane potential and to establish ionic gradients across the membrane.  These 
proteins include inwardly rectifying K
+
 channels, which function to set the resting 
potential[50], as well as proteins that hydrolyze ATP to derive energy for ion exchange 
including Na
+
, K
+
 and Ca
2+
- ATPases[51-53].  There are a number of K
+ 
channels where 
debate still remains on their exact role in the cardiac AP.  This group includes "leak" K
+
 
channels that may contribute to maintaining cellular osmolarity[50], and K(ATP) 
channels that are sensitive to intracellular ATP levels and may link metabolism to 
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electrical function[54].  A number of these channels are active during other phases of the 
AP but their exact contributions are less understood than that of the voltage-dependent 
channels mentioned previously.  The vast distribution of Kv isoforms throughout the heart 
plays a vital role in the repolarization of cardiomyocytes that contributes to E-C coupling 
and cardiac conduction.  While there are stark differences between the roles of each 
isoform in human and mouse cardiac repolarization, the isoforms expressed in both 
species are closely homologous.  Based on this, the mouse is a useful, although imperfect, 
model to study human cardiac electrical signaling[47].   
Cardiac conduction occurs via the cable-like coupling of individual myocytes.  
Electrical signaling is propagated from cell to cell through low-resistant, large multimeric 
protein pores called gap junctions.  Each gap junction is formed by the combination of 2 
hexameric hemichannels (connexons) assembled from 6 connexin (Cx) proteins[55].  
Cardiac gap junctions generally consist of the Cx isoforms Cx40, Cx42 and Cx45, which 
demonstrate regional differences in expression[55].  As each myocyte depolarizes, the 
electrical signal is propagated from cell-to-cell through gap junctions.  Cardiac 
conduction is initiated by a small group of pacemaker cells found in the sinoatrial (SA) 
node that contain hyperpolarization activated, cyclic nucleotide-gated (HCN) non-
specific cation channels[56, 57].  HCN along with Kv, and Cav function to produce long 
lasting rhythmic depolarizations in the SA node that travel through the atria via the 
interatrial tract (Bachman's bundle) or through one of three internodal pathways that carry 
the cardiac AP to another pacemaker region: the atrioventricular (AV) node (Fig. 1.3).  
The AV node acts as a secondary pacemaker to the SA node and depolarizes at a slower 
rate.   
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Figure 1.3: Cardiac conduction.  Cardiac electrical signaling begins in the sinoatrial 
node and follows a discreet pathway through the heart.  Figure from Kerwin, 2007 
reprinted with permission.  http://afibcryoablation.com/types.of.arrhythmia.asp 
 
Conduction travels from the AV node to the His-Purkinje fiber system and then 
throughout the ventricular myocardium.  Purkinje fiber cells also demonstrate pacemaker 
function but are the slowest and considered tertiary pacemakers.  The cardiac AP 
propagates through the ventricles from the endocardium to the epicardium leading to the 
depolarization of ventricular myocytes.  As Nav and Cav inactivate, due to the prolonged 
depolarization, the cells enter a period of effective refractory where additional stimulus 
has no effect on the cellular AP.  As the cell repolarizes, through the action of Kv, it 
enters a period of relative refractory where an AP can fire but with a smaller magnitude.  
The redundancy in refractory period prevents tetanus, which can occur in skeletal muscle 
and neurons, as well as reentrant conduction as a result of ectopic beats.  Cardiac 
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conduction can be observed with electrocardiograms (ECGs) that describe the change in 
voltage across the heart as a function of time.  The cardiac AP as recorded by an ECG is 
the result of electrical activity in each excitable cell of the heart and the coupling of that 
activity through gap junctions.  The ECG has a number of identifiable features that can 
reveal a great deal about the function of the heart (Fig. 1.4).  The P wave is the main 
electrical vector as it travels from the SA node to the AV node and through the atria.  The 
QRS complex represents the depolarization of the ventricles.  The interval between the 
beginning of the P wave and the beginning of the QRS complex describes the time it 
takes for the electrical impulse to travel from the SA to AV node.  The T wave follows 
the QRS complex and represents the repolarization of the ventricles.  The time that the 
ventricles are depolarized is represented by the ST segment and in healthy hearts is 
isoelectric.  The interval between the beginning of the QRS complex and the end of the T 
wave, the QT interval, is an important indicator of heart health.  Shortened and prolonged 
QT intervals are arrhythmogenic and may predispose one to sudden death[59-61]. 
 
 
 
Figure 1.4: Representative electrocardiogram.  ECGs demonstrate the change in 
voltage across the heart as a function of time.  Figure modified from Nerbonne and 
Kass[58] reprinted with permission.   
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Deviations in normal cardiac electrical activity, or arrhythmias, affect at least 5 
million people in America and contribute to the mortality of at least 400,000 
annually[62].  Arrhythmias have diverse etiologies and are typically characterized by the 
location in the heart where they occur and the type: tachycardia (speeding up of the heart 
beat), bradycardia (slowing of the heart) or block, where the electrical impulse 
(conduction) cannot travel through its normal pathway.  Changes in pacemaker activity 
play a large role in the genesis of arrhythmias and can be described by a change in rate, 
or more dangerously, by the formation of ectopic pacemaker activity.  A prolonged 
depolarization can cause atrial and ventricular myocytes to act as pacemakers.  This 
occurs because Nav are inactivated but Cav and Kv are still functioning.  The prolonged 
depolarization can allow Cav to recover from inactivation and re-activate.  The result is a 
depolarization that occurs during phase 2 or 3 of the AP [early after depolarization 
(EAD)].  Additionally, during phase 4 of the AP, persistent cytosolic Ca
2+
 can activate 
the sodium calcium exchanger causing a depolarizing current and a delayed after 
depolarization (DAD).  Successive DADs can cause extra systoles, which may lead to 
ventricular tachycardia and potentially to the rapid and chaotic contraction of the 
ventricles (fibrillation).  Ventricular fibrillation is life-threatening without medical 
intervention.  The impedance of cardiac conduction (conduction block) along with 
ectopic pacemaker activity may contribute to reentrant conduction (reentry).  Reentry is 
characterized by conduction loops and can lead to fibrillation of the atria and ventricles.  
An ECG is an important indicator of cardiac electrical health; however, it does not 
always elucidate the etiology of an arrhythmia.  For example, a lengthening of the QT 
interval [long QT (LQT)] and Brugada syndrome, which has 3 unique ECG patterns, can 
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both be caused by any number of acquired or congenital pathologies[63, 64].  There is an 
array of diseases that were linked to arrhythmias including high blood pressure, diabetes, 
coronary artery disease and myocardial infarction and ischemia[65-68].  Many of these 
diseases lead to structural changes in the heart such as hypertrophy or scarring that can 
impact conduction outflow.  Not surprisingly, pathological changes or differences in Nav 
and Kv function significantly impact cardiac function and arrhythmogenesis.  Congenital 
defects in VGIC genes of otherwise healthy individuals cause arrhythmias[69].  As an 
example, there are a number of conserved mutations in the human Nav1.5 gene that are 
responsible for both Brugada syndrome as well a LQT type 3(LQT3)[70].  Additionally, 
mutations in the Kv11.1 gene (hERG) can cause both LQT and short QT (SQT) 
syndromes[71, 72].  Kv11.1 is also an important mediator in drug-induced LQT syndrome 
so much so that every drug that is released in the U.S. must be tested 
electrophysiologically for reactivity with the hERG gene product.  Nav and Kv mediated 
arrhythmias occur as a result of other acquired etiologies.  Diseases that cause heart 
failure or structural changes such as hypertrophy are, in and of themselves, pro-
arrhythmic.; however, there may be secondary effects that specifically alter VGIC 
expression and function, which exacerbates the condition.  Human cardiac hypertrophy is 
associated with a decrease in Ito and LQT[73].  Animals models of pressure-overload 
cause changes in Kv gene expression and can abolish the transmural expression of 
Kv4.3[74-78].  Pressure-overload models have also demonstrated an effect on Nav 
expression and INa characteristics[79-81].  Heart failure and hypertrophy can cause 
activation of the renin-angiotensin-aldosterone-system (RAAS).  Activation of RAAS is 
at first compensatory but becomes pathological through chronic stimulation.  RAAS 
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decreases Ito in experimental models[82, 83] and can increase INa and voltage-gate Ca
2+
 
current (ICa)[84-87].  Diabetes is associated with a down-regulation of Ito and a shift in Kv 
isoforms in human and animal models[66, 88, 89].  Unusual cardiac activation itself, such 
as tachycardia, can also cause changes in VGIC expression/function[90, 91].  Overall, 
alterations in VGIC expression contribute to remodeling and are important mediators in 
arrhythmogenesis.  Cardiac conduction includes the concerted actions of all ion channels 
and transporters, including VGICs, in an individual cell as well as specific regions of the 
heart.  While some redundancy exists, without the proper density and function of all 
channel types, the susceptibility to re-entrant current and arrhythmias is greatly increased.   
 
1.3. Excitability is influenced by di- and multivalent ionic species 
The studies of Hodgkin, Huxley and Katz during the 1940s and 50s, using the 
axon of giant squid, imparted important principals to the understanding of cardiac 
electrical signaling.  The ideas that cells are selectively permeable to ionic species and 
that ionic flux is dependent on voltage changes are vital to understanding cardiac 
physiology.  The studies were prologue to how biophysical approaches could be used to 
investigate the function of the heart including the role of electrostatic interactions and 
electrical driving force.  These methods can be utilized as they are in ECG recordings to 
observe cardiac activity as well as to offer insight into pathological changes in function.  
As in example many patients that suffer from ionic imbalances, such as hyper- or 
hypocalcemia, show signs of altered electrical activity including arrhythmias, ECG 
abnormalities, paralysis and tetany[92-94].  Interestingly, in a study reported five years 
following the initial Hodgkin and Huxley reports using the axon of squid, 
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Frankenhaeuser and Hodgkin observed that when the extracellular Ca
2+
 concentration 
[Cao
2+
] was increased, cellular excitability decreased (Fig. 1.5)[95].  A number of studies 
followed the Frankenhaeuser and Hodgkin report of the dampening effect of increased 
[Cao
2+
] and regardless of the channel or tissue type studied, the same type of decrease in 
VGIC activity was observed[23, 96-109].  In many of the studies, other divalent or 
multivalent cations were used to produce similar effects.  The data often showed a 
uniform, rightward shift in all voltage-dependent gating parameters.   
 
Figure 1.5: External Ca
2+
 shifts VGIC activation voltage.  Decreased external [Ca
2+
] 
results in a 10-30 mV shift in squid giant axon Na
+
 current activation voltage.  From B. 
Frankenhaeuser and A.L. Hodgkin[95] reprinted with permission. 
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Despite investigations into the effect of increased divalent cation concentration on 
cellular excitability proceeding long after the experiments performed by Frankenhaeuser 
and Hodgkin, it was a suggestion by their colleague A.F. Huxley following those initial 
studies that offered the first and most prevailing explanation of the phenomenon.  As 
stated in the Frankenhaeuser and Hodgkin work[95], Huxley proposed, “that calcium ions 
may be absorbed to the outer edge of the membrane and thereby create an electric field 
inside the membrane which adds to that provided by the resting potential.”  It was this 
suggestion that would develop into what is known as the surface potential theory, a 
theory that would help shape the manner in which VGIC gating was studied in the years 
to come[23].   
 
1.4. Surface potential theory predicts external negative surface charge contributes to 
channel gating 
VGICs are transmembrane proteins that must be partially soluble in an ion-rich 
aqueous environment.  Their solubility depends on the presence of significant numbers of 
polar or ionized functional groups on the channels or in close proximity to them.  The net 
electric field created by the various ionic groups arranged across or near the membrane 
influences the resting membrane potential.  The fundamental principal of the surface 
potential theory is defined by this phenomenon.  Consistent with the dampening effect 
imposed by increased [Cao
2+
] on excitability, extracellular negative surface charges 
contribute to the surface potential and thereby to the membrane potential[23, 102, 110-
113].  Because of the nature of cellular membranes and the distribution of polar and 
ionized functional groups throughout them, there may be a great deal of heterogeneity in 
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the spatial arrangement and magnitude of the negative surface charge[114, 115].  
Biophysicists utilized models created by Louis Georges Gouy and David Chapman 
(Gouy-Chapman model) to study hypothetical planar surfaces bearing a uniform charge 
immersed in a salt solution in order to quantify the membrane surface charge[116, 117].  
However, the Gouy-Chapman model only considered the charge of the ionic species and 
did not take into account potential chemical interactions of the electrolytes in the solution 
and molecules fixed to the membrane[116-118].  Later, the Stern modification was added 
to the Gouy-Chapman model to take into account the potential binding of molecules 
including the reversible interaction between acidic groups and protons or metal 
cations[118, 119].  Based on the Gouy-Chapman-Stern model, one can predict that when 
the extracellular solution is high in cations particularly di- or multivalent species, the 
negative surface charge will be masked or shielded, thus abolishing the contribution of 
the negative surface charge to the membrane potential.  The observations of 
Frankenhaeuser and Hodgkin and those who followed describing the effect of increased 
cations and the subsequent decrease in excitability can be explained by the shielding (and 
perhaps, binding) of negative surface charge which would essentially act to hyperpolarize 
the membrane compared to when the negative surface charge was free to exert its effect 
on the membrane potential (see figure 1.6 and Hille, 2001[23] for details).   
 
1.5. What contributes to the negative surface charge? 
 One major source of ionic species in a membrane is the phosphate head groups of 
the phospholipid bilayer.   
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Figure 1.6: External net negative surface potential impacts membrane potential 
sensed by VGIC.  Illustration of the putative effects of external negative charges on the 
electric field and resulting membrane potential.  Surface potential theory predicts that 
increases in external divalent cations nullifies the impact of the surface charge on 
membrane potential.  Figure from B. Hille [23] page 650 reprinted with permission. 
 
McLaughlin et al. demonstrated that phospholipids bathed in a salt solution have surface 
potentials ranging from -40 to -120 millivolts (mV).  Interestingly it was calculated that 
the local [Ca
2+
] was as much as 10
4
 times greater at the surface of the bilayer compared 
to the rest of the solution[111, 120-123].  Later, the effect of negatively charged 
membrane phospholipids on Nav activity was investigated directly by expression of the 
channel in lipid bilayers that either contained phosphate groups or did not.  It was 
determined that in the presence of higher (7.5 mM) [Cao
2+
], the half activation voltage 
(Va) was shifted rightward by 17 mV in the neutral bilayer and by 25 mV in the 
negatively charged bilayer[124].  The data suggested that negatively charged 
phospholipids contribute to the surface potential, and based on the relative shifts in Va in 
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the presence of high [Cao
2+
], it is reasonable to assume that external negative charges 
other than phospholipids had a greater impact on Nav gating than did the charged bilayer.   
As the sequences and structures of VGICs were uncovered, a number of studies 
provided a possible explanation for the apparent additional sources of negative surface 
charges.  Elinder and Arhem detailed a common motif of acidic amino acids in a key 
extracellular location on multiple Kv isoforms.  They proposed that the depolarizing shift 
in the voltage dependent properties of Kv caused by increased divalent cation 
concentrations was due to charge shielding of glutamate and aspartate residues found on 
the loop between the fifth transmembrane segment (S5) and the pore helix[109, 125-127].  
Elinder and Arhem’s hypothesis offered a quantifiable explanation of the apparent 
additional surface charge found on VGICs.  They did not however consider the 
contribution of other charged molecules.   
In the early 1980s a number of studies were performed investigating the 
tetrodotoxin (TTX) sensitivity of Nav in the electric eel electrophorus electricus.  It was 
discovered that the binding of TTX occurred on the channel itself[128] and through 
biochemical analyses, that the Nav were extensively modified by extracellular 
glycosylation, up to 30% of the total channel weight[128-130].  In subsequent 
experiments utilizing enzymes that recognize and cleave specific carbohydrate residues, 
it was determined that a large proportion, as many as a 100 residues, consisted of the 
carbohydrate derivative N-acetylneuraminic acid or sialic acid[131, 132].  Sialic acids 
belong to a group of 9 carbon chain sugar molecules in which many are substituted with 
an acetylated amine group at C5 and a carboxylic acid that is deprotonated and negatively 
charged at physiological pH at C1[133].  Those who first discovered the unusually high 
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levels of negatively charged sugars attached to the Nav of electric eels were likely 
intrigued by the potential contribution of sialic acids to the surface potential and to VGIC 
function.   
 
1.6. Glycosylation is a sequential process  
 As synthesis of a nascent integral membrane protein such as a VGIC begins, it is 
quickly recognized by a signal sequence of specific nonpolar amino acids located in the 
N-terminus that targets it for translocation into the endoplasmic reticulum (ER)[134].  
Translation continues with the ribosome attached to the ER and the growing protein 
inserted further into the lumen.  Translocation of a protein into the ER is required for 
subsequent trafficking of the protein and for the necessary protein processing including 
glycosylation, which occurs on essentially every integral membrane or secretory 
protein[135].  Extracellular protein glycosylation occurs through two mechanisms: 1) N-
glycosylation, in which an N-acetyl glucosamine (GlcNAc) is covalently bonded to an 
asparagine residue that serves to initiate a three amino acid consensus N-glycosylation 
sequence that consists also of any second amino acid, except proline, and ends with a 
serine or threonine residue (NXS/T)[137] or or 2) O-glycosylation that involves the 
covalent addition of an N-acetyl galactosamine (GalNAc) to a serine or threonine without 
any other known sequence requirements[138], although recent studies suggested 
“permissive” sequences[139, 140].  In the case of N-glycosylation (Fig. 1.7[136]), when 
the NXS/T sequence is recognized by specific enzymes located in the ER, a block of 14 
simple carbohydrates is transferred to the growing protein from a dolichol phosphate 
molecule donor consisting of 20 isoprene units attached to the luminal wall of the 
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ER[141, 142].  Thus, N-glycosylation can be more accurately described as a co-
translational modification as opposed to its usual moniker of a post-translational 
modification at least for the initial steps of the process.  The en bloc carbohydrate 
structure, consisting of two GlcNAcs, nine mannoses and three glucose residues, is 
processed by removal of all three glucose residues in a sequential manner[143].  In many 
primitive species the high mannose structure is the final glycan structure; however, in 
more sophisticated organisms, N-linked glycosylation continues in the distal ER and 
Golgi with the formation of more complex glycan structures beginning with mannose 
trimming through mannosidase activity (Fig. 1.7)[137, 143].  O-linked glycosylation does 
not require the en bloc addition of multiple sugar residues.  Only a single GalNAc is 
required for initiation, which is added in the ER; all further glycosylation is thought to 
occur in the Golgi[137, 139].   
Figure 1.7: Extracellular glycosylation is a sequential process that occurs in the ER 
and Golgi and involves the activity of hundreds of glycogene products.  Illustration of 
the process of protein N-glycosylation as it occurs in the ER and Golgi.  Figure from A. 
Helenius and M. Aebi[136].  Reprinted with permission from AAAS. 
22 
 
Following initiation of both N- and O-glycosylation, additional carbohydrate 
residues are added in a regulated and sequential manner as the protein travels through the 
cis, medial and trans cisternae of the Golgi.  Enzymes, referred to as 
glycosyltransferases, add sugars from carbohydrate-nucleotide donors to their substrates 
with specific covalent linkages[144], which in many cases can form large multi-antennae 
carbohydrate branches.  Glycosyltransferases are localized in different regions of the 
Golgi; therefore, the type and amount of sugars that are added to the glycan structures 
depends on where the nascent proteins leave the Golgi complex and on the relative 
expression/location of the glycosyltransferases[145], which, as will be discussed in more 
detail in the following sections, can differ among cell types and species[146].  More 
recently there are reports of glycosyltransferases that function in the cytoplasm and at the 
plasma membrane, which would increase the ability of a cell to augment glycosylation 
and perhaps even alter it in response to certain stimuli[137].  In addition, there are a 
variety of glycosidases responsible for removing certain sugar residues by cleaving 
specific linkages[147-150].   
 
1.7. The terminal residues attached to glycans are sialic acids 
Many complex carbohydrate branches terminate with the addition of sialic acids 
through the activity of various sialytransferases.  Sialic acids can demonstrate striking 
structural variability with approximately 50 known isomers[151] although common to 
almost all is a negative charge at physiological pH originating from a deprotonated 
carboxylic acid that, while dependent upon the other substituted side groups, possesses a 
pKa of approximately 2.6[152].  Sialytransferases also demonstrate great variability.  
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Presently there are 20 different cloned mammalian sialytransferases that are organized in 
four groups by their substrate and linkage specificity: β-galactoside α2,3, β-galactoside 
α2,6, GalNAc α2,6 and α2,8[153].  The α2,8 group of sialytransferases are 
polysialytransferases that can link polymers of sialic acids to a single sialic acid residue, 
leading to the formation of large, complex and heavily sialylated proteins.  For example, 
in addition to the approximately 100 polysialic acids found on the Nav of E. electricus 
mentioned previously, there are reports of neuronal cell adhesion molecules (NCAM) 
with as many as 200 polysialic acid residues attached[132, 154].  Data suggest that sialic 
acid processing can continue at the membrane surface; a family of endogenous sialidases 
were identified that can remove sialic acids from transmembrane proteins although the 
purpose and mechanisms of these enzymes are poorly understood[155, 156].  Further, in 
certain cell types, extracellular sialyltransferase activity may create the potential for the 
dynamic regulation of protein sialylation[157-160].  Collectively, the process of 
glycosylation provides an opportunity for great diversity in glycan structures and levels 
and types of attached sialic acids, leading to the potential for a large and variable deposit 
of negative charge located on the external surface of the plasma membrane. 
 
1.8. Role of glycans in cellular communication 
 Genes involved in glycosylation (glycogenes) represent 1-2% of the mammalian 
genome and function to create a wide range of glycan structures unique to individual 
organisms[161].  Cell and species recognition depends on the specificity of glycan 
structures which function as a molecular component of cellular communication.  Such 
communication serves many physiological purposes including immune responses to 
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exogenous and endogenous pathogens, receptor activation, cell adhesion, endocytosis and 
molecular trafficking.  While deficiencies or alterations in glycosylation generally do not 
produce significant phenotypes in vitro, diseases of glycosylation lead to serious 
morphological, functional and developmental deficits clinically and in mouse 
models[161].  One family of diseases known as the congenital disorders of glycosylation 
(CDGs), which includes ~ 40 different isotypes, can affect both N- and O- linked 
glycosylation and is caused by congenital defects in glycogenes resulting in 
hypoglycosylation[162].  The mutated glycosylation structure(s) vary among CDG, but 
reduced glycoprotein sialylation is common to nearly all.  CDGs can lead to severe 
defects in many of the body’s systems, particularly the nervous[163, 164] and 
cardiovascular[165] systems, and many forms of the disease lead to a high prevalence of 
infant mortality[166].  Additionally, muscular dystrophies, which many include in the 
family of CDGs, cause impairments in neuromuscular development and function[167]. 
 
1.9. How does sialic acid modulate voltage-gated Na
+
 channel activity? 
 It did not take long following the discovery that Nav from E. electricus were 
heavily glycosylated and more specifically heavily sialylated to question if the negatively 
charged sialic acids played a physiological role in the activity of the channel.  In 1990 
Recio-Pinto et al. expressed the purified channel in lipid bilayers and found that when the 
protein was treated with the glycosidase neuraminidase, which cleaves sialic acid 
residues, significant depolarizing shifts in voltage dependent channel activation were 
observed[168].  At the time, it was difficult to determine whether the change in channel 
function caused by desialylation was due to a change in protein structure and stability or 
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was specifically related to the decrease in negatively charged sialic acids.  Further, the 
bilayer studies required treatments to limit Nav inactivation, thus preventing the complete 
assessment of channel gating ± sialic acids.  Based on the studies by Frankenhaeuser and 
Hodgkin and others, the surface potential theory was put forth as a potential mechanism.  
It seemed apparent that such a large deposit of negative charge located somewhere near 
the external surface of the membrane (although this is not known) might impact the 
activity of VGICs.  Indeed 15 years later, a study utilizing a number of rigorous 
biochemical techniques demonstrated that the removal of sialic acids from Nav caused no 
significant effect on channel structure or stability and that the effect of sialic acids on 
channel function was strictly mediated through electrostatic interactions[169].  In 1997, 
Bennett et al. demonstrated similar effects of desialylation on the activity of mammalian 
skeletal muscle Nav (rSkM1, or Nav1.4) expressed in Chinese hamster ovary (CHO) cells 
using three independent methods to reduce channel sialylation.   
 
Figure 1.8: Reduced sialylation of the skeletal muscle Nav through three 
independent methods produced nearly identical shifts in all voltage-dependent 
gating mechanisms.  Conductance-voltage (G-V) relationships for Nav1.4 expressed 
under conditions of full sialylation (+SA) and three independent conditions of reduced 
sialylation (-SA; neuraminidase-treated, to remove sialic acids (left), in the essentially 
non-sialylating Lec2 cell line (middle), and two deletion mutants in which four or five N-
glycosylation sites were removed (right).  Adapted from E .Bennett et al.[170] reprinted 
with permission. 
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Enzymatic removal of sialic acids, expression of the channel in a sialylation-deficient cell 
line (Lec2[171, 172]) and deletion of a 24 and 30 amino acid region of DIS5-S6 that 
contained four and five putative N-glycosylation sites, respectively, led to similar 
depolarizing shifts in all voltage-dependent properties of the channel (Fig. 1.8) [170].  
Additionally, the depolarizing shifts in channel gating caused by increased divalent cation 
concentration were ameliorated significantly in the absence of sialic acids indicating that 
sialic acids contributed to the dampening effect of increased divalent cations on 
excitability (Fig.1.6).  This phenomenon demonstrates the principal behind the surface 
potential theory and how it relates to sialic acids; that is, the presence of extracellular 
negatively charged molecules (sialic acids) causes the membrane around the channel to 
be slightly depolarized.  The local, slight depolarization primes the VGIC requiring a 
smaller change in membrane potential to induce channel gating.  When the extracellular 
solution is high in di- or multivalent cations, the negative charges of the sialic acids are 
likely shielded through electrostatic and molecular interactions as described by the Gouy-
Chapman-Stern model.  The initial studies investigating the effects of sialic acids on Nav 
activity provided a striking example of how protein processing can lead to sophisticated 
forms of regulation on not only the specialized Nav found in the electric eel but also on 
mammalian isoforms. 
 
1.10. The effect of sialic acids on Nav gating is dependent on the specific Nav isoform 
 Nearly all VGIC isoforms are uniquely glycosylated.  For example, up to 30% of 
the mature molecular mass of the Nav isoforms found predominately in skeletal muscle 
and neurons are comprised of sugar residues, while the primary Nav isoform found in 
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cardiac tissue (Nav1.5) is reported to be approximately only 5% carbohydrate[173].  Such 
diversity among isoforms may arise from the differences in the number/location of 
glycosylation sites (glycosylation signatures) on the different isoforms and/or the extent 
of glycosylation that occurs in the Golgi.  Considering the differences in glycosylation 
levels and gating properties of the various Nav isoforms and following the initial 
observation that rSkM1 activity was regulated by sialylation, potential isoform-specific 
effects of glycosylation on different Nav was questioned.  In 1999, Zhang et al. 
investigated how reduced sialylation differentially affects rSkM1 and the human cardiac 
Nav1.5 (hH1A)[174].  Reducing sialylation of hH1A depolarized the Va by 9 mV and 
depolarized the mid-point of the steady-state inactivation (SSI) curve and the voltage of 
half-inactivation (Vi), by 12 mV.  Reduction in the levels of sialic acid on rSkM1 caused 
an 8 mV depolarizing shift in activation and a 4 mV hyperpolarizing shift in SSI, which 
was the first report of a hyperpolarizing shift in VGIC gating caused by a reduction in 
negative surface charge.  In 2002, the effects of reduced sialylation on the human skeletal 
muscle Nav (hSkM1; Nav1.4) and hH1A were investigated utilizing CHO cells[175].  The 
study reported that desialylation of hSkM1 led to 11-15 mV depolarizing shifts in 
conductance-voltage (G-V) and SSI relationships as well as in the Va, Vi, the rate of fast 
inactivation and the rate of recovery from fast inactivation.  There were no changes in the 
gating parameters of hH1 following desialylation.  Immunoblot analyses indicated that 
both channels are glycosylated but hSkM1 possesses greater levels of glycosylation and 
sialylation.  Electrophysiological recordings in the presence of high [Cao
2+
] suggested 
that sialic acids altered hSkM1 gating thorough electrostatic interactions.  Chimeras were 
created in which the heavily glycosylated DIS5-S6 loops of hSKM1 and hH1 were 
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exchanged (creating, hSkM1P1 and hH1P1, respectively).  Simply by replacing the 
hSkM1 DIS5-S6 loop with the hH1 DIS5-S6 loop, the voltage-dependent gating of 
hSKM1P1 was unaffected by changes in sialylation.  However, gating of the converse 
chimera, in which the hH1 DIS5-S6 loop was replaced with the hSKM1 DIS5-S6 loop 
(hH1P1) was modulated by changes in channel sialylation.  That is, a switch in gating 
phenotype from sialic acid sensitive to insensitive (and vice-versa) was achieved by 
swapping the DIS5-S6 loops between two Nav isoforms that were differently sensitive to 
changes in channel sialylation.  These data suggested that the sialic acid residues relevant 
to modulation of Nav gating were localized to the DIS5-S6 loop.   
In a study by Johnson et al. in 2004, the gating of four different Nav isoforms was 
investigated[176].  Consistent with the previous report[175], the more heavily 
glycosylated Nav1.4 demonstrated the largest depolarizing shifts in gating midpoints 
following desialylation, while NaV1.5, which is apparently the least glycosylated Nav 
isoform, was unaffected by desialylation as expressed in CHO cells.  Two neuronal Nav 
isoforms Nav1.2 and Nav1.7, which are moderately glycosylated in relation to Nav1.4 and 
Nav1.5, displayed correspondingly moderate depolarizing shifts in gating midpoints 
following desialylation.  The results of this study suggested a dose response like 
relationship between the levels of sialylation and the observed effects on channel gating; 
this is discussed in more detail later.  Together, these data suggest that the glycosylation 
of Nav affects function in an isoform specific manner and, based on the discrepancy in 
results observed between the Satin and Bennett groups[174-176], that desialylation can 
affect the same Nav differently depending on the cell type in which the isoform is 
expressed.  Satin’s group expressed the cloned channels in human embryonic kidney 
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(HEK) cells while the Bennett group utilized CHO cells.  Both findings imply that some 
of the biophysical properties that differentiate VGICs may be due to differing levels of 
glycosylation and that the process of glycosylation is regulated and dependent on the type 
of cell where the glycosylation occurs.  This idea of cell-specific regulated glycosylation 
was later investigated and supported by several studies that will be discussed in more 
detail in a later section[177-179]. 
 
1.11. Sialic acids attached to heavily glycosylated Nav β subunits impact Nav α 
subunit gating 
The α or pore forming subunit of Nav, like other types of VGICs, typically 
interact with various auxiliary or β subunits.  In many cases, β subunits are vital to the 
correct trafficking and insertion of the α subunits and can modulate conductance and 
gating[180-182].  A number of studies indicate that when Nav α subunits are co-expressed 
with β subunits, channel activity is altered in an isoform and stoichiometric dependent 
manner[182, 183].  Nav β subunits are transmembrane glycoproteins.  In 2004, Johnson et 
al. demonstrated that co-expression of the fully sialylated β1 isoform caused a 
hyperpolarization of the G-V and SSI relationships of Nav1.5, Nav1.2 and Nav1.7[176].  
The presence of β1 had no effect on gating of the heavily sialylated Nav1.4.  Additionally, 
the fully sialylated β1 subunit increased the rate of fast inactivation and slowed the rate of 
recovery from fast inactivation for Nav1.5, Nav1.2 and Nav1.7.  The hyperpolarizing 
effect of the β1 subunit on Nav α subunit gating was abolished under conditions of 
reduced sialylation, suggesting that β1 sialic acids were responsible for the modulatory 
effect of β1 on Nav1.5, Nav1.2 and Nav1.7 gating.  Further, the authors prevented N-
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glycosylation of β1 through mutation of all four putative N-glycosylation sites.  This 
proved sufficient to prevent any effect of β1 on gating of the Nav α subunits.  Together, 
these data indicated that β1 subunit modulation of Nav1.5, Nav1.2 and Nav1.7 was 
mediated fully through β1 sialic acids imposing a hyperpolarizing effect on α subunit 
voltage-dependent gating.  To help determine whether the modulatory effect of β1 sialic 
acids was due to an electrostatic mechanism, gating of the fully sialylated Nav α subunit, 
when co-expressed with β1, was the most sensitive to changes in [Cao
2+
], suggesting that 
β1 sialic acids contribute to the surface charge that impacts Nav α subunit gating. 
Interestingly, when the glycosylation levels of the heavily glycosylated Nav1.4 (that was 
unaffected by β1 co-expression), were reduced through construction of the hSkM1P1 
chimera, fully sialylated β1 co-expression caused a hyperpolarization of the G-V and SSI 
relationships, mimicking the effects of β1 on the Nav1.5, Nav1.2 and Nav1.7 isoforms.  
These data suggested that the impact of sialic acids on Nav gating is an additive and 
saturating phenomenon involving α and β subunit sialic acids. 
In a later study, Johnson and Bennett investigated whether the β2 isoform affected 
Nav1.5 and Nav1.2 gating[184].  The study reported that β2 co-expression caused a sialic 
acid dependent hyperpolarizing shift in Nav1.5 gating but not in Nav1.2 gating.  
Additionally, when β1 and β2 were expressed together with Nav1.5, the two β subunits 
acted synergistically to cause an additive sialic acid dependent hyperpolarization of 
Nav1.5 gating.  Previous to these two studies, the effect of sialylation on Nav function was 
attributed only to sialic acids found on the α subunits.  The data obtained investigating 
the effects of β1 and β2 on Nav1.4, Nav1.5, Nav1.2 and Nav1.7 were the first to show that 
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auxiliary subunits could also contribute to the surface potential experienced by Nav, and 
do so through apparent saturating β subunit-specific mechanisms. 
 
1.12. Sialic acids have a similar effect on Kv activity 
 Concurrent with the studies investigating Nav glycosylation, the functional effects 
of glycosylation and sialylation were also being investigated on Kv.  In 1996 Thornhill et 
al., observed that the rat Kv1.1 isoform was functionally affected by sialylation.  The 
removal of sialic acids using neuraminidase, expression of the channel in the sialylation-
deficient Lec2 cell line or a CHO cell line in which glycoproteins and glycolipids are 
missing the terminal galactose and sialic acid residues, (Lec8)[172, 185], shifted the Va to 
more depolarized potentials and slowed the kinetics of the channel in an electrostatic 
dependent manner[186].  Later, single channel analysis of Kv1.1 indicated that the 
depolarizing effect of desialylation on the gating of macroscopic currents was similarly 
observed at the single channel level as described by an 8mV depolarized shift in the 
fractional open time (fo) and a shallower fo-voltage slope of a glycosylation deficient 
Kv1.1 mutant compared to the wild type with no observed change in the maximal 
conductance[187].  Kv1.1 and Kv1.2 are homologous Kv isoforms found predominately in 
the brain and shown to possess sialic acid-rich glycan structures[188, 189].  In 2007 the 
role of sialylation in Kv1.2 function was investigated through a novel approach; that is, 
previous studies investigating the effects of VGIC sialylation were performed by 
reducing the levels of sialic acids or exchanging the functionally relevant glycosylation 
sites with those of more heavily glycosylated isoforms[190].  In this study, mutants were 
created where glycosylation sites were added to the channel and compared to the function 
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of the wild type channel.  Addition of two N-linked sites to Kv1.2, giving the channel a 
total of three sites, caused the Va to be hyperpolarized by 5mV, steepened the slope of the 
G-V relationship and increased the rate of activation and inactivation.  An additional 
mutant was created that lacked the single putative N-linked glycosylation site.  
Subsequent experiments on the N-linked deficient mutant demonstrated a depolarizing 
shift in Va, a broadening of the slope of the G-V curve and decreased channel kinetics.  
The effects of altered sialylation on channel function were sensitive to increased divalent 
cation concentration. 
In 2008, Johnson and Bennett observed that gating of the Drosophila shaker KV, 
ShB, was depolarized under conditions of reduced sialylation[191].  The group went on 
to show that the contribution of sialic acids to the channel’s function was likely mediated 
through an electrostatic mechanism.  Interestingly, only recently was it shown that 
Drosophila sialylates proteins[192].  Subsequent studies were performed on other Kv 
isoforms and demonstrated that, similar to its effects on Nav activity, sialylation 
modulates Kv function in an isoform specific manner.  A 2001 study by Ufret-Vincenty et 
al. indicated that the Kv isoforms (likely, Kv4.2/4.3[193]) responsible for Ito,f in the adult 
mouse heart were affected by desialylation[194].  A depolarizing shift in activation and a 
decrease in current density of Ito,f were observed following neuraminidase treatment of 
adult mouse ventricular cardiomyocytes.  In the same study, recombinant Kv4.3 was 
expressed in the fully glycosylating parental CHO cell line and the sialylation-deficient 
Lec2 line, with data indicating a similar depolarizing effect on voltage dependent 
activation of Kv4.3 expressed in Lec2 cells. Ufret-Vincenty et al. also questioned the 
possible contribution of sialylated lipids to the surface potential finding that the sialic 
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acids that had the most prominent effect on KV4.3 function were those found on 
glycoproteins (likely the channel itself) and that sialylated glycolipids did not 
significantly affect channel activity.  In 2010, Schwetz et al. showed that voltage 
dependent activation but not inactivation of Kv1.5 was shifted to hyperpolarized 
potentials by sialic acids through electrostatic mechanisms.  However, Kv1.4 was not 
similarly affected by sialylation (at least in CHO cells)[195].  
 
1.13. Sialic acids linked to O-glycans also modulate VGIC gating 
 Recently, Schwetz et al. investigated the effect of sialylation on the 
heterologously expressed Kv isoforms Kv2.1, Kv4.2 and Kv4.3[196].  As mentioned 
previously, protein glycosylation occurs in either an N- or O-linked manner and because 
of the complexity and lack of a consensus O-linked sequence, prior studies investigating 
the effects of sialic acids on VGIC function were limited to N-linked glycosylation or 
generic sialylation.  Kv4.2 and Kv4.3 possess no N-linked glycosylation sites and while 
Kv2.1 does possess a single N-linked site, based on recent structural data, it is highly 
unlikely that it is N-glycosylated[197, 198].  The report indicated that reduced sialylation 
depolarized the G-V curves and Va by 16, 8 and 9 mV for Kv4.2, Kv4.3 and Kv2.1, 
respectively, but had no effect on SSI.  Electrophysiological experiments were repeated 
in the presence of high extracellular Ca
2+
 and indicated that the effect of reduced 
sialylation was mediated through electrostatic mechanisms.  Biochemical experiments 
utilizing glycosidase gel shift analyses and Click chemistry[199] demonstrated that none 
of the three isoforms were N-glycosylated but all were O-glycosylated and sialylated, 
indicating for the first time that O-linked sialic acids impact VGIC function.   
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1.14. Sialic acids modulate VGIC gating through subunit-specific mechanisms 
 Gating of VGICs are altered by sugars attached to channels in an isoform-specific 
manner, likely due to each isoform’s (and/or auxiliary subunit’s) unique set of potential 
glycosylation sites, or the glycosylation signature.  Most studies established that the 
sugar-dependent gating effects were imposed by the terminal residues attached to N- and 
O-glycans, sialic acid.  Often, an electrostatic mechanism was assigned with negatively 
charged sialic acids contributing to a surface potential, causing channels to gate at less 
depolarized potentials.  With the regulated expression of VGIC α subunit isoforms, each 
with their unique glycosylation signature, together with various combinations of auxiliary 
subunits that are each uniquely glycosylated, gating of VGICs can be modulated through 
subunit-specific differential sialylation that can potentially alter channel function through 
multiple mechanisms.    
 
1.15. Data suggest that cellular environment may impact how sialic acids modulate 
channel gating 
 The effect of sialic acids on VGIC function appears to be determined, at least in 
part, by the cell type in which the glycosylation occurs.  As described above, the 
glycosylation process is complex, with the activity of hundreds of glycogenes responsible 
for channel glycosylation.  Thus, the presence and/or activities of the glycogenes are 
likely regulated and different among cell types, and this will determine the types and 
levels of glycans attached to expressed proteins.  For example, independent studies 
investigating the glycosylation of two different proteins expressed in either CHO or HEK 
cells indicated significantly greater levels of glycosylation attached to proteins expressed 
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in CHO cells[200, 201].  The study also showed increased total CHO cell sialylation and 
different sialic acid linkages between the two cell lines[201].  These data offer a possible 
explanation for the apparently conflicting results between the Satin and Bennett groups 
where the former observed significant changes in the voltage dependent properties of 
Nav1.5 under conditions of reduced sialylation while the latter only observed a change in 
gating when Nav1.5 was expressed with β subunits[174-176].  Additionally, Zhang et al. 
observed a hyperpolarizing shift in SSI of Nav1.4 while the Bennett groups observed a 
marked depolarizing effect of desialylation on Nav1.4 SSI.  It is interesting to consider 
that perhaps the differences in sialic acid linkages occurring in the CHO and HEK cells, 
as observed by Suen et al., or perhaps differences in overall activity of sialytransferases 
between the two cell lines, may also contribute to surface charge based on the spatial 
configuration of extracellular sialic acids.  This idea of cell-specific effects of 
glycosylation on channel function is further supported by comparing the data obtained 
using expression systems to that observed from studies investigating the sialylation-
mediated effects on Nav1.5 gating in native cardiac myocytes.  First, Ufret-Vincenty et al. 
indicated that enzymatic removal of sialic acids from adult mouse ventricular myocytes 
caused a depolarization of Va and hyperpolarized SSI[202].  Secondly, the Bennett lab 
showed in one report that sialic acids attached to Nav1.5 expressed in CHO cells had no 
effect on channel gating, while, in a second report showed that Nav1.5 expressed in 
neonatal and adult atria as well as in adult ventricles (but not in neonatal ventricles), was 
sensitive to desialylation[177, 178].  In 1999, Shi and Trimmer described an isoform 
specific effect on Kv glycosylation when comparing native and heterologously expressed 
channels[188].  Additionally in two similar studies, natively expressed neuronal Kv were 
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also shown to be differentially glycosylated and uniquely sialylated.  A report in 2008 
demonstrated that the KV isoforms 3.1, 3.3 and 3.4 show variation in the levels and 
perhaps types of glycan structures attached to each isoform that was dependent on the 
brain region from which the proteins were isolated[203].  This included the spinal cord, 
hypothalamus thalamus, cerebral cortex, hippocampus, and cerebellum of adult rats.  A 
subsequent study in 2009 by Cartwright and Schwalbe demonstrated that Kv3.1, Kv3.3, 
Kv3.4, Kv1.1, Kv1.2 and Kv1.4, isolated from adult rat brains, all contained significant 
levels of sialic acids[189].  It was also determined that the Kv3 proteins contained α2,3 
and atypical α2,8 sialyl-linkages and that at least one of the multi-antennae glycan 
structures possessed sialic acid polymers.  Contrastingly, the Kv1 isoforms had only α2,8 
sialyl-linkages.  Both families of Kv isoforms had sialic acids linked to internal 
carbohydrate residues, which was previously only thought to occur on gangliosides.  The 
authors suggested that the presence of these atypical sialic acid linkages would play a role 
in “modulating and fine tuning the excitable properties of neurons in the nervous 
system.”  Collectively the described observations suggest that glycosylation is regulated, 
which is an important phenomenon that will be expanded upon in the proceeding 
sections. 
 
1.16. The extent of channel sialylation is apparently cell-specific and changes during 
development 
The majority of data discussed thus far concerning VGIC sialylation originated 
from studies utilizing recombinant proteins expressed in immortalized cell lines or lipid 
bilayers.  These data described important functional consequences of VGIC sialylation 
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and provided insight into the probable electrostatic mechanism by which sialic acids 
modulate VGIC gating.  Additionally, the previously described studies introduced the 
notion that channel activity is modulated differently depending on the type of cell in 
which the protein is expressed; this is likely linked to the types and levels of sialylation 
that occur differentially among cell types.  How do these phenomena translate to native 
biological systems and whole organism physiology?  In 2001, Tyrrell et al. reported that 
the glycosylation state of Nav1.9 changes between neonate and adult rat dorsal root 
ganglia (DRG) neurons[179].  Western blotting indicated that neonatal DRG neurons 
possess a higher molecular weight Nav1.9 that is sensitive to deglycosylation compared to 
adults, suggesting that the neonate DRG Nav1.9 is more sialylated than the adult channel.  
Voltage-clamp experiments on isolated neonatal and adult DRG neurons indicated that 
the Vi for Nav1.9 was hyperpolarized in neonatal neurons compared to adult neurons.  
Removal of sialic acids resulted in the Vi for neonatal Nav1.9 being shifted to values 
similar to the adult channel Vi, but had no effect on gating of the adult Nav.  Nav1.9 
displays a great deal of overlap between voltage dependent activation and inactivation 
resulting in a relatively large window current[27, 204].  Because of this larger window 
current, it is thought that the neonatal Nav1.9 sets the membrane potential and threshold 
level for action potential firing in DRG neurons[205, 206].  The authors hypothesized 
that the sialic acid-mediated hyperpolarization of SSI in neonatal rat DRG neurons should 
increase the window current and thereby increase the persistent Nav activity.  In support 
of the developmental regulation of VGIC sialylation in the brain, a report by Castillo et 
al. in 1998 described a hyperpolarizing change in Va of Nav isolated from rat forebrains 
and expressed in lipid bilayers as the animals increased in age[207].  Single channel 
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conductance was also altered in channel protein isolated from the adult compared to 
protein isolated from the PO and P15 aged rats as described by a significantly shorter fo.  
Western blotting indicated that the channel protein was of higher molecular weight as the 
developmental stage increased suggesting that glycosylation increased throughout 
development of the forebrain.  The physiological purpose of altering sialylation levels of 
Nav is unknown but, as Tyrell et al. noted, it may cause differential responses to similar 
stimuli through development. 
In 2006, a study investigating the activities of Nav1.5 in the rat myocardium 
showed that all voltage-dependent channel gating parameters measured from isolated 
neonatal ventricular myocytes were depolarized compared to Nav1.5 gating parameters 
measured from isolated neonatal atrial and adult ventricular and atrial myocytes[178].  
The investigators hypothesized that the differences in gating were due to differing levels 
of sialic acids found on the channels.  Enzymatic removal of sialic acids and of all N-
linked glycosylation using neuraminidase and the enzyme PNGase-F, respectively, 
shifted similarly all Nav1.5 voltage-dependent gating parameters measured from neonatal 
atrial and adult atrial and ventricular myocytes to values equivalent to those of neonatal 
ventricular Nav1.5.  Desialylation and deglycosylation had no effect on Nav from neonatal 
ventricles.  Comparative gel shift analyses suggested that there were approximately 15 
more sialic acid residues attached to the neonatal atrial and adult Nav1.5 than were 
attached to the less sialylated neonatal ventricular channel.  Thus, the data support that a 
difference of ~15 sialic acid residues attached to Nav1.5 is fully responsible for the 
observed hyperpolarizing shifts in Nav1.5 gating.  These data support the idea that VGIC 
39 
 
glycosylation is variable among cell types, is regulated during development and such 
regulated glycosylation modulates VGIC gating. 
In an attempt to better understand the role of regulated glycosylation in normal 
cardiac physiology and electrical signaling, a study by Montpetit et al. in 2009 observed 
that 110 of 239 glycogenes were significantly differentially expressed among neonatal 
and adult atrial and ventricular myocytes[177].  Mass spectrometry of atrial and 
ventricular protein taken from neonatal and adult mouse hearts showed significant 
changes in the types and relative densities of N-glycans, particularly in sialic acid 
isotypes as well as in sialyl-linkages, demonstrating a remodeling of the cardiac glycome 
among the different myocyte types.  This was in agreement with the observed changes in 
glycogene profiles.  One of the genes demonstrating regulated expression, α-N-acetyl-
neuraminide α-2,8-sialyltransferase 2 (ST8Sia2), is a polysialytransferase found only in 
the neonatal atria among the groups tested.  To determine if changes in glycogene 
expression could lead to functional differences in electrical excitability, the authors 
utilized a knock-out (KO) strain homologously deficient in ST8Sia2 (ST8Sia2
−/−
).  
Current-clamp experiments showed significantly longer AP duration (APD) in atrial 
myocytes isolated from ST8Sia2
−/−
 neonatal mice compared to wild type controls.  There 
were no differences in the APD of neonatal ventricular myocytes among the two groups 
(ST8Sia2 is not expressed in the neonatal ventricle).  In addition to an extension of APD, 
the time to AP peak was significantly longer in ST8Sia2
-/-
 neonatal atrial myocytes 
compared to controls with no difference in time to AP peak observed in ventricular 
myocytes.  Alterations in the initiation or upstroke of the AP suggest that Nav function 
may be affected.  Indeed, whole-cell voltage-clamp experiments demonstrated a ~7mV 
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depolarizing shift in G-V and SSI curves, Va and Vi as well as a slowing of fast 
inactivation and a more rapid recovery from fast inactivation for atrial ST8Sia2
−/−
 Nav 
gating, consistent with other studies investigating the role of sialylation in Nav function 
and with the data from the AP recordings.  No differences in ventricular Nav gating were 
observed between ST8Sia2
−/−
 and control mice.  There were also no changes in cell 
capacitance or current density among any of the cell types investigated.  Immunoblot gel 
shift analyses indicated that the level of Nav sialylation is greater in control atria than in 
ST8Sia2
−/−
 atria.  Additionally, endoneuraminidase (EndoN) treatment, used to remove 
polysialic acid chains of five or more residues, indicated that only the control atrial Nav 
was polysialylated.  These data suggested that ST8sia2 expression and function result in 
increased Nav sialylation that modulates Nav gating and contributes to altered AP 
waveforms.  The results of the study suggested that the regulated expression of only one 
of more than 100 glycogenes has functional consequences on cardiac electrical signaling.  
 
1.17. Regulated sialylation modulates excitability through two mechanisms 
Thus, there are two proposed mechanisms by which regulated sialylation 
modulates excitability: a subunit-specific mechanism (with changes in expression levels 
of specific, glycosylated isoforms) and regulated (aberrant) changes in the ability of the 
cell to glycosylate VGICs.  Both mechanisms may occur simultaneously to produce a 
spectrum of possible ion channel gating mechanisms.  There is considerable evidence that 
suggests differential sialylation has a range of effects on various voltage-dependent 
gating mechanisms which would result in a much larger spectrum of possible VGIC 
gating motifs.  The consequences of such mechanisms of regulated glycosylation, 
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particularly sialylation, is predicted to result in a greater level of complexity of the 
orchestrated and summated activity of these ion channels, leading to altered AP 
waveforms, and ultimately to changes in excitability and conduction. 
 
1.18. Differential sialylation likely occurs dynamically and across a spectrum of 
rates 
The previously described studies together suggest that developmental and cell 
specific alterations in sialylation have functional consequences on VGIC gating.  From 
these data, one might infer that regulated sialylation occurs over a developmental 
timeframe or at the rate of protein synthesis.  However, there is evidence that both 
mechanisms of differential ion channel sialylation may take place on a more dynamic 
time scale.  For example, internalized surface proteins might reenter directly into the 
Golgi glycosylation pathway and be differently sialylated[208].  There is also evidence 
that extracellular sialyltransferase and glycosidase expression is regulated and their 
activities may rapidly change the level of glycosylation attached to glycoproteins, 
resulting in a change in VGIC function[159, 209-213].  In 2007, Isaev et al, reported that 
hippocampal network excitability is modulated by endogenous neuraminidase that 
removes external sialic acids[214].  If extracellular glycosyltransferase and/or 
glycosidase activity is relevant to neuronal function, this might lead to rapid adjustments 
to surface channel sialylation.  Thus, the rate of modulation of ion channel gating 
imposed through regulated sialylation would occur across a spectrum of rates, ranging 
from relatively rapid changes in surface glycan structures to the slower rate of protein 
synthesis to the much slower time course of development.   
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1.19. The role of aberrant glycosylation/sialylation in cardiac pathology 
There are a number of diseases that are caused by aberrant changes in 
protein/lipid glycosylation, which in turn, can and often do, lead to reduced sialylation.  
Nearly all CDGs are associated with hypotonia and many are associated with more 
specific electrical maladies such as arrhythmias and epileptiform activity or seizures[215-
217].  There are also examples of acquired pathologies that may affect glycosylation, 
which then may contribute to the disease symptoms.  Chagas disease is caused by a 
eukaryotic parasite that produces a trans-sialidase that can remove sialic acids from 
mammalian cells[218, 219].  Those afflicted with Chagas disease suffer from arrhythmias 
and present with aberrant ECG patterns[220-223].  In other studies, Chronic tachycardia, 
resulting in heart failure, induced changes in the glycosylation of the calcium binding 
protein calsequestrin[224] and aberrant Nav sialylation was linked to the progression of 
cardiac dysfunction in a mouse model of heart failure[202].  The development of type II 
diabetes induced by a high fat diet caused changes in the glycosylation state of the 
glucose transporter responsible for glucose-stimulated-insulin-release in the pancreas, 
which acerbated the condition[225].  Together, many of these examples illustrate how 
glycosylation is susceptible to seemingly unrelated disease states possibly through 
deviations in normal biochemical pathways or Golgi/ER stress that are often incurred by 
such pathologies[226, 227].  It is interesting to note that these examples are also often 
associated with electrical remodeling[228, 229], which highlights the idea that changes in 
glycosylation, caused by such diseases, may contribute to the pathomechanisms. 
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1.20. Developing a model to study the effects of aberrant glycosylation/sialylation on 
cardiac excitability  
 The use of the ST8Sia2
-/-
 strain led to interesting insight into the role of 
developmentally regulated sialylation and how it pertains to Nav function and myocyte 
electrical signaling in the neonatal atria.  In contrast to the expression of ST8Sia2, which 
is only expressed in the neonatal mouse atria, the sialyltransferase β-galactoside α-2,3-
sialyltransferase 4 (ST3Gal4) is uniformly expressed across the developing and adult 
myocardium.  The enzyme is responsible for adding a sialic acid to galactose residues 
through an α-2,3-linkgage that can be linked to core N- or O-linked glycans[153, 177, 
230].  ST3Gal4 is 1 of 6 ST3Gals all of which possessing unique specificities involving 
both glycoproteins and glycolipids (Fig. 1.9)[153]. 
 
Figure 1.9: Function of the sialyltransferase ST3Gal4.  A, Schematic diagram 
comparing substrate specificities of ST3Gal4 (circled) and five other ST3Gal enzymes.  
Figure modified from Varki et al. Essentials of Glycobiology[231] reprinted with 
permission.  B, ST3Gal4 adds a SA (Neu5Ac) to galactose residues (Gal) through an α2-
3 linkage.  Figured modified from Kanehisa et al.[232, 233] reprinted with permission.  
http://www.genome.jp/kegg-bin/show_pathway?map00513  
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In order to question how aberrant sialylation may affect electrical excitability, which is 
consistently observed in diseases of glycosylation, in the adult mouse left ventricle, a 
transgenic strain homozygous for a null-ST3Gal4 transgene (ST3Gal4
-/-
) was used.  
Additionally, these studies began to investigate the role of individual glycogene products 
and how they relate to Nav and Kv function as well as cardiac electrical signaling.  Based 
on preliminary data discussed in the introduction describing variable and isoform-specific 
effects of reduced sialylation on Nav and Kv gating, channel function was assessed in 
cardiomyocytes isolated from the left ventricular apex (LVA) of adult ST3Gal4
-/-
 mice 
and compared to WT controls using the whole-cell voltage-clamp recording technique.  
The study also explored potential differences in cellular electrical signaling using whole-
cell current-clamp recordings techniques.  Through the use of biochemical techniques, 
the following attempted to discern direct changes in sialylation of the various Nav and Kv 
isoforms present in mouse ventricular myocytes between the two groups.  Finally, based 
on potential differences in channel function and cellular excitability, the study 
investigated how aberrant sialylation may lead to changes in cardiac and ventricular 
conduction through the use of ECG and optical mapping techniques. 
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Chapter 2 
Materials and Methods 
 
2.1. Generation of the ST3Gal4
-/- 
transgenic strain 
 ST3Gal4 is 1 of 20 sialytransferases[153, 177].  The ST3Gal4 deficient strain is 
healthy, viable and displays no obvious phenotype[234].  Among other functions, the 
enzyme is an important mediator in hemostasis, leukocyte arrest and selectin ligand 
formation[234-241].  Creation and characterization of the ST3Gal4 deficient
 
mouse was 
performed by others previously[234] and generously provided by Dr. Jamey Marth.  In 
order to genotype the animals used in this study, genomic DNA was extracted from tail 
snips using the REDExtract-N-Amp tissue PCR kit (Sigma XNATR) following the 
manufactures directions.  Genotypes were determined using standard PCR methods with 
the following three primers: GAC GCC ATC CAC CTA TGA G, GGC TGC TCC CAT 
TCC ACT and GGC TCT TTG TGG GAC CAT CAG. 
 
2.2. Cardiac myocyte isolation 
 Adult (12-14 weeks old) male mice homozygous for the normal ST3Gal4 gene 
(WT) and ST3Gal4
-/-
 mice were anaesthetized using isoflurane (5%) then euthanized by 
cervical dislocation.  Hearts were rapidly excised from the body and cannulated through 
the aorta.  Using a modified Langendorff apparatus, the hearts were perfused and 
digested with the following solutions for the indicated times at 36 ± 1°C: 5 minutes with 
Hank’s Balanced Salt Solution (HBSS) (Cellgro 21-022) supplemented with 10 
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millimoles per liter (mM) of N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid 
(HEPES) from a 1 molar stock (Cellgro 25-060), 1 mM MgCl2 from a 1 molar stock 
(Ambion AM9530G) and 1 mM CaCl2, pH 7.4; 10 minutes with HBSS supplemented 
with 10 mM HEPES and 1 mM MgCl2, pH 7.4; 20 minutes with HBSS supplemented 
with 10 mM HEPES, 1 mM MgCl2,  0.1% bovine serum albumin (BSA), 0.025 mM 
CaCl2, 20 mM taurine and type 2 collagenase (80 units/ml; Worthington CLS-2), pH 7.4; 
and 5 minutes with a high K
+
 solution containing 100 mM K
+ 
glutamate, 10 mM K
+ 
aspartate, 25 mM KCl,  10 mM KH2PO4,  2 mM MgSO4, 20 mM taurine, 5 mM creatine 
base, 0.5 mM ethylene glycol tetra acetic acid (EGTA),  5 mM HEPES, 0.1% BSA,  and 
20 mM glucose, pH 7.2 as described by others[242].  At the completion of the perfusion 
scheme described above, the bottom 2 millimeters of the LVA was cut and dispersed in 
the high K
+
 solution for approximately 10 minutes to obtain individual myocytes.  The 
suspension was filtered and cells were allowed to sediment by gravity.  Myocytes were 
maintained at room temperature in the high K
+
 solution until use 1-4 hours following 
isolation. 
 
2.3. Electrophysiology 
0.2-0.5 ml of the myocyte suspension were added to a recording chamber (Warner 
RC-26) mounted on a Nikon TE200 microscope.  Cells were allowed to settle for 5 
minutes on laminin (BD 354232) coated cover slips.  Once the cells adhered, 
approximately 5 volumes of extracellular recording solution (ECS) were perfused 
through the chamber.  Patch pipettes were fabricated using a horizontal pipette puller 
(Sutter P97), filled with an intracellular recording solution (ICS) and mounted on a 
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headstage (Axon Instruments CV203BU).  Immediately prior to seal formation, the 
solid/liquid junction offset was zeroed manually using the pipette offset on an Axopatch 
200B amplifier with β set to 0.1.  Following seal formation of at least one gigaohm, the 
whole cell-configuration of the patch clamp method was obtained[243].  Analog signals 
recorded by the amplifier were low-pass filtered at 5 kilohertz (kHz) then digitized at a 
rate of 50 kHz using a Digidata 1440A analog/digital interface connected to a personal 
computer. For recording INa in voltage-clamp mode, cell size was determined by 
integrating the capacitance of the cell following a 25 ms 10 mV step in voltage from a 
holding potential of -100 mV.  After measuring cell size, resistances and capacitances 
were minimized manually using the amplifier and oscilloscope found in the Axon 
Clampex 10.2 software.  Patch Pipettes (Warner G150F-3) had a mean series resistance 
of approximately 1.4 ± 0.1 (n=24) megaohms (MΩ) when filled with an ICS (Table 1).  
All solutions were filtered (0.22 microns) and either stored at -20˚ C (ICS) or 4˚ C (ECS) 
Series resistances were compensated for as necessary but to a minimum of 80%.  The 
currents were leak subtracted using the P/5 method from the holding potential of -100 
mV and in the opposite polarity as the current waveforms.  The maximum mean voltage 
errors from uncompensated series resistances were approximately -6.5 ± 0.6 and -6.0 ± 
0.7 mV when recording from control (n=11) and ST3Gal4
-/-
 (n=13) LVA myocytes 
respectively and were ignored.  The ECS used to record INa is found in table 1; an 
ICS/ECS junction potential of -0.5 mV was calculated using the junction potential 
calculator in Clampex and was also ignored.   
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Table 2.1: Electrophysiological recording solutions 
 INa 
ICS 
7.2 
CsOH 
INa 
ECS 
7.35 
CsOH 
Cell 
Refract 
ICS 
7.2  
NaOH 
Cell 
Refract 
ECS 
7.4  
NaOH 
IK 
ICS 
7.2 
KOH 
IK  
ECS 
7.4 
NaOH 
AP 
 ICS 
7.2 
KOH 
AP 
ECS 
7.4 
NaOH 
Millimoles/Liter 
CsCl 25.0 130.0 -- -- -- -- -- -- 
CsF 110.0 -- -- -- -- -- -- -- 
EGTA 10.0 -- -- -- 10.0 -- 10.0 -- 
HEPES 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
MgATP  5.0 -- 5.0 -- 1.0 -- 1.0 -- 
Glucose 5.0 10.0 5.0 10.0 5.0 10.0 5.0 10.0 
NaCl 5.0 11.0 8.0 130.0 -- 136.0 -- 130.0 
CaCl2 -- 0.5 -- 1.0 -- 0.5 -- 1.0 
MgCl2 -- 1.0 -- 1.0 -- 1.0 -- 1.0 
CdCl2 -- 0.3 -- -- -- 0.25 -- -- 
KAsp -- -- 110.0 -- -- -- -- -- 
KCl -- -- 20.0 5.4 135 5.4 135 5.4 
Na2HP04 -- -- -- 0.33 -- -- -- 0.33 
K2ATP -- -- -- -- 4.1 -- 4.1 -- 
TTX -- -- -- -- -- 0.02 -- -- 
Table 1 Legend: INa, voltage-gated sodium current; ICS, intracellular recording solution; 
CsOH, cesium hydroxide; ECS, extracellular recoding solution; Cell Refract, cellular 
refractory period; NaOH, sodium hydroxide; IK,voltage-gated potassium current; KOH, 
potassium hydroxide; AP, action potential; CsCl, cesium chloride; CsF, cesium fluoride; 
HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid; MgATP, magnesium 
triphosphate; NaCl, sodium chloride; CaCl2, calcium chloride; MgCl2, magnesium 
chloride; CdCl2, cadmium chloride; KAsp, potassium aspartate; KCl, potassium chloride; 
Na2HPO4, sodium phosphate dibasic; K2ATP, potassium triphosphate; TTX, tetrodotoxin.    
 
For recording cellular refractory period in current-clamp mode, patch pipettes (Chase 
502) had a mean series resistance of approximately 2.5 ± 0.03 (n=26) MΩ from a holding 
potential of -70 mV when filled with an ICS (Table 1).  The cellular refractory period 
ECS is found in table 1 and the ICS/ECS junction potential was calculated to be 
approximately -21 mV and was added off-line.  When recoding IK in voltage-clamp 
mode, cell capacitances were calculated as described above but from a holding potential 
of -70 mV.  Patch pipettes (Chase 502) had a mean series resistance of 2.9 ± 0.2 MΩ 
(n=20).  Leak currents were always less than 80 pA and were ignored.  The ICS/ECS 
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(Table 1) junction potential was 4.4 mV and was also ignored.  Series resistances and 
capacitances were minimized as described above and were compensated to a minimum 
value of 80%.  The maximum voltage errors from uncompensated series resistances were 
-8.0 ± 1.0 and 7.4 ± 1.3 mV for WT and ST3Gal4
-/-
 respectively (n=10) and were 
ignored.  To record APs in current-clamp mode, patch pipettes had a mean series 
resistance of 2.6 ± 0.3 MΩ (n=18) from a holding potential of -70 mV.  The ICS/ECS 
(Table 1) was calculated to have a junction potential of -4.8 mV and was added offline.  
Voltage and current clamp protocols were written and executed using Clampex 10.2 and 
the ICS was allowed to dialyze for 5 minutes following cell rupture.  
 
2.4. Voltage clamp protocols: INa 
 
Current density and conductance-voltage relationships: INa 
 Cells were held at -100 mV then depolarized by a series of voltage steps 
beginning at -85 mV and ending at 30 mV for 120 ms in 5 mV increments.  Each voltage 
step was separated by 1.5 seconds and the current was leak subtracted using the P/5 
method from the holding potential and in the opposite polarity as the current waveform.  
The current elicited from each test pulse was divided by the cell capacitance to report 
current density as A/F or the current was divided by the driving force using the following 
equation to determine Na
+
 conductance (G): 
 G = INa / (Vpot -Vrev) 
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where INa is the sodium current at each test potential, Vpot is the test potential and Vrev is 
the Nernst equation-derived reversal potential at 22° C (20.05 mV).  Conductance-
voltage relationships were fit with a Boltzmann equation of the form: 
Fraction of Maximum Conductance (G/Gmax) = [1+ (e 
–
((Vpot -Va)/Ka))] 
-1 
where Gmax is the maximum theoretical conductance, Va is the voltage of half-activation 
and Ka is the slope of the Boltzmann fit for activation as previously described[178].  The 
Gmax, Va, and Ka for each cell were determined by fitting the single cell data to a single 
Boltzmann distribution, and were used to determine the mean parameter values among 
cells as listed in Table 1.  Also, the Gmax was used to normalize cellular data.   
 
Voltage-dependent inactivation: INa 
 Cells were held at -100 mV and subjected to conditioning voltage pulses ranging 
from -140 mV to -65 mV in 5 mV increments for 500 ms.  Following the conditioning 
pulses, the cells were depolarized to -20 mV for 10 ms.  Currents were normalized to the 
maximum current and the data were fit with the following Boltzmann equation: 
Fraction of Maximum Current (I/Imax) = [1+ (e 
–
((Vpot-Vi)/Ki))] 
-1 
where I/Imax is the ratio of each current to the maximum current, Vpot is the potential of 
each conditioning pulse, Vi is the voltage of half-inactivation and Ki is the slope of the 
Boltzmann fit for inactivation as previously described[178].  The Imax, Vi, and Ki for each 
cell were determined by fitting the single cell data to a single Boltzmann distribution, and 
were used to determine the mean parameter values among cells as listed in Table 3.    
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Time constants of fast inactivation (inact): INa 
 The attenuating portion of the current traces recorded during the current 
density/conductance-voltage measurements were fit with a single exponential function 
with the form: 
f(t) = Ae
-t/tau
 + C 
where A is the amplitude in picoamps (pA), t is the time in ms, tau is the time in ms it 
takes for the current to inactivate one exponential unit and C is a constant.   
 
Time constants for recovery from fast inactivation (rec): INa 
 Two distinct recovery protocols were performed and in both cases, cells were held 
at a voltage of -100 mV then depolarized to -20 mV for 50 ms.  In one of the protocols 
the membrane potential was returned to -100 mV for a duration of initially 1 then a delta 
of 5 ms followed by a second depolarization to -20 mV for 50 ms.  In the second 
protocol, following the initial pulse to -20 mV, the membrane potential was changed to -
90 mV for a duration of initially 10 then at a delta of 10 ms followed by a second pulse to 
-20 mV for 50 ms.  Between each pulse the membrane potential was returned to -100 mV 
for 4 seconds.  The current elicited from the second pulse to -20 mV was normalized to 
the current from the initial pulse to -20 mV for each sweep.  The data was fit with a 
single term exponential with the form: 
I2/I1 = A(1-e
-t/tau
) + C 
where I2/I1 is the ratio of the current elicited from the second -20 mV pulse to the current 
elicited from the initial -20 mV pulse, A is the asymptote of the curve, t is the time in ms, 
tau is the time it takes the curve to rise one exponential unit and C is a constant.  In some 
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cases, curve fitting was marginally improved when a bi-exponential function was used. 
However, in many cases such a fit provided nonsensical results; therefore, a single 
exponential was used in these studies. 
 
2.5. Cellular refractory period 
 Following cell rupture, the membrane potential was measured.  Cells were 
injected with positive current for a duration of 4 ms with an initial current step of 100 pA 
followed by subsequent current steps with a delta of 50 pA.  Each sweep was separated 
by 2 s.  Threshold was determined by the first overshooting AP that preceded at least two 
more similar action potentials.  The threshold current was calculated and a current 
amount of 125% of threshold was used in a two pulse protocol to estimate the cellular 
refractory period.  Cells were stimulated with a current pulse of 125% of threshold for 4 
ms followed by a second pulse 5 ms later and then each additional pulse came with a 
delta of 8 ms.  The pulse number that elicited an overshooting AP that preceded at least 2 
more similar APs was used to estimate the refractory period.   
 
2.6. Voltage clamp protocols: IK 
 
Current density and conductance-voltage relationships: IK 
 Cells were held at -70 mV then depolarized by a series of voltage steps beginning 
at -50 mV and ending at 50 mV for 4.5 seconds in 10 mV increments.  Each voltage step 
was separated by 10 seconds.  The decaying portion of each current trace was fit with the 
following bi-exponential function: 
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f(t) = IKslow e
-t/tau1
 + Ito e
-t/tau2
 + ISS 
where IKslow is the amplitude of the slowly inactivating portion of each current trace, t is 
the time in ms, tau1 is the time it takes IKslow to inactivate one exponential unit, Ito is the 
amplitude of the rapidly inactivating portion of each current trace, tau2 is the time in ms 
it takes Ito to inactivate one exponential unit and ISS is the amplitude of the non-
inactivating portion of each current trace.  This method, as a means to delineate the 
different IK in the mouse ventricle, was described by others previously[31].  The 
amplitudes of each kinetic component, derived from the above equation, for each current 
trace were divided by the cell capacitance to report current density as A/F or the current 
was divided by the driving force using the following equation to determine conductance 
(G): 
G = I / (Vpot -Vrev) 
where I is the current at each test potential, Vpot is the test potential and Vrev is the Nernst 
equation-derived reversal potential at 22°C (83.4 mV).  Conductance-voltage 
relationships were fit with a Boltzmann equation of the form: 
Fraction of Maximum Conductance (G/Gmax) = [1+ (e 
–
((Vpot -Va)/Ka))] 
-1 
where Gmax is the maximum theoretical conductance, Va is the voltage of half-activation 
and Ka is the slope of the Boltzmann fit for activation as previously described[178].  The 
Gmax, Va, and Ka for each cell and current type (kinetic component) were determined by 
fitting the single cell data to a single Boltzmann distribution, and were used to determine 
the mean parameter values among cells as listed in Table 4.  Also, the Gmax was used to 
normalize cellular data.   
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Voltage-dependent inactivation: IK 
 Cells were held at -70 mV and subjected to conditioning voltage pulses ranging 
from -110 mV to 0 mV in 10 mV increments for 10 seconds.  Following the conditioning 
pulses, the cells were depolarized to 30 mV for 4.5 seconds.  Each sweep was separated 
by 10 seconds.  Decaying portion of each current trace elicited from each voltage step to 
30 mV was fit with a bi-exponential function as described above.  The maximum 
amplitudes of each current type (kinetic components) from each current trace were 
normalized to their corresponding maximum values from the first step to 30 mV.  The 
data were fit with either a single Boltzmann equation for Ito or a double Boltzmann 
equation for IKslow: 
Fraction of Maximum Current Ito (I/Imax) = [1+ (e 
–
((Vpot-Vi)/Ki))] 
-1 
Fraction of Maximum Current IKslow (I/Imax) =  
[(1+ (e 
–
((Vpot-Vi1)/Ki1))) +(1+ (e 
–
((Vpot-Vi2)/Ki2)))] 
-1 
where I/Imax is the ratio of each current to the maximum current, Vpot is the potential of 
each conditioning pulse, Vi1 and Vi2 are the voltages of half-inactivation and Ki1 and Ki2 
are the slopes of the Boltzmann fit for inactivation as previously described[178].  The 
Imax, Vi, and Ki for each cell and for each current type were determined by fitting the 
single cell data to a single Boltzmann distribution, and were used to determine the mean 
parameter values among cells as listed in Table 4.    
 
Time constants of inactivation (inact): IK 
 The time constants of inactivation were recorded from the bi-exponential fit as 
described above used to calculated current densities and G-V values.  IKslow is represented 
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by tau1 and Ito is represented by tau2.  Where tau is the time in ms it takes for the current 
to inactivate one exponential unit. 
 
2.7. Action potential recordings 
 Following cell rupture, the membrane potential was measured.  Cells were 
injected with positive current for a duration of 4 ms with an initial current step of 100 pA 
followed by subsequent current steps with a delta of 50 pA.  Each sweep was separated 
by 2 s.  Threshold was determined by the first overshooting AP that preceded at least two 
more similar action potentials.  The threshold current was calculated and a current 
amount of 125% of threshold was used to measure AP parameters (Table 5).  The mean 
values from five replicate current pulses of 125% of threshold delivered for a duration of 
4 ms at 0.25 Hz were calculated. 
 
2.8. Optical mapping 
Left ventricular epicardial conduction was studied using optical mapping methods 
similar to that previously described[244-246].  Following anesthesia with isoflurane (5%) 
adult ST3Gal4
-/-
 and WT mice were euthanized by cervical dislocation.  Hearts were 
rapidly excised, cannulated through the aorta and perfused with a Kreb’s solution at 
37°C.  Following equilibration, healthy hearts were stained with a voltage sensitive 
fluorescent dye, RH237 (Biotium).  A green light (20-Watt green LED passing through 
an additional 520 ± 25 nm filter) excited the dye.  An optical mapping system with two 
CMOS monochrome data cameras (Ultima, Scimedia) collected the fluorescence from a 
6x6 mm
2
 area on the epicardial surface of the left ventricle, converted it to electrical 
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signals and then recorded movies of APs (690 nm long-pass filtered) at 500 frames/sec. A 
bipolar electrode was placed on the left ventricular epicardium to deliver stimulating 2 
ms pulses.  The stimulation threshold was determined first by repetitively stimulating the 
heart with progressively decreasing current until cardiac activation was no longer 
observed.  Subsequent stimulations used 2x the activation threshold.  To determine the 
minimum refractory period, the heart was stimulated repetitively with progressively 
decreasing S1-S2 pacing intervals until the S2 stimulus failed to stimulate a response.  
Conduction velocity was measured (using BV-ANA software, Scimedia) along a line 
starting at or near the site of stimulation and perpendicular to the smoothest conduction 
wavefronts.  To determine susceptibility to arrhythmias, the heart was stimulated 
repetitively using trains of 2-6 pulses at intervals 5 ms longer than the measured 
refractory period.  Recorded data were analyzed using visual identification to characterize 
pacing induced arrhythmias, including, ventricular tachycardia (V.Tach., at least a 
doubling of the rate), reentry (observed as an anomalous conduction loop), 
afterdepolarization (observed as an aberrant excitation event), and/or ventricular 
fibrillation (V. Fib.).  Optical mapping data was collected by Kofi-Kermit Horton and 
Jiashin Wu and analyzed by Jiashin Wu. 
 
2.9. Electrocardiograms 
 Adult (12-14 week) mice were anesthetized with isoflurane (5%) and transmitters 
(DSI TA10ETA-F20) were implanted into the abdominal cavity.  The leads were sutured 
to muscles in upper right section of the thorax and near the apex of the heart.  The 
animals were allowed to recover for one week following the surgery.  ECGs were 
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recorded from conscious unrestrained mice continuously over 48 hour periods using 
telemetry via a data exchange matrix (PhysioTel Receivers RPC-1).  Recorded data was 
analyzed using Data Quest ART and Ponemah (DSI PNM-P3P-ECG) software.  Analysis 
of the ECGs included comparison of the specific characteristics such as RR interval 
(heart rate), PR segment, QT segment (when possible) and P wave characteristics.  
Analysis will also include observations of the ECG waveforms to investigate for aberrant 
conduction events that will include premature ventricular contractions, heart rate 
variability and anomalous conduction/arrhythmias.  For studies involving isoproterenol, a 
stock solution was made by dissolving the appropriate amount of isoproterenol into 
normal saline followed by filtration (0.22 microns).  Working solutions were then made 
by diluted with normal saline and dosages were delivered intraperitoneally.   
 
2.10. Membrane protein enrichment 
 Adult male WT and ST3Gal4
-/-
 mice between the ages of 12 and 14 weeks were 
anaesthetized using isoflurane then euthanized by cervical dislocation.  The lower 2/3 of 
the heart consisting of both the right and left ventricles was separated and then snap 
frozen in liquid nitrogen.  The following protocol, which was previously described by 
others[247], and solutions were all performed and maintained at 4° C.  Two hearts per 
group were homogenized using glass douncers and sonication in 3 ml of extraction 
solution consisting of 20 mM trishydroxymethylaminomethane (Tris)-base, 5 mM 
Ethylene diamine tetra acetic acid (EDTA), 0.8 mM benzamidine, 1 mM iodacetamide, 
1.1 μM leupeptin, 0.7 μM pepstatin, 76.8 nM aprotinin and 0.5 mM  
phenylmethanesulfonylfluoride; pH 7.5.  The suspension was centrifuged at 1000xG for 
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ten minutes and the supernatant was aspirated.  The pellet was re-homogenized in 2.5 ml 
of extraction solution and centrifuged at 1000xG for ten minutes.  Both supernatants were 
pooled and centrifuged at 40,000xG for ten minutes.  The resultant pellet was suspended 
in extraction solution supplemented with 0.6 molar KCl for ten minutes to dissociate the 
cytoskeleton.  The suspension was centrifuged at 40,000xG for ten minutes and the pellet 
was suspended in extraction solution; this was repeated twice to ensure the removal of 
KCl.  The final pellet was solubilized in extraction solution supplemented with 2% Triton 
X-100 for 1 hour with periodic sonication.  The suspension was centrifuged at 10,000xG 
for 10 minutes and the supernatant was aspirated.  Protein concentrations were 
determined using a BCA assay (Pierce 23237) and the protein solutions were stored at -
80° C until use. 
 
2.11. Western blotting and immunodetection  
 Western blotting for densitometry analysis was performed using protocols 
adapted from Invitrogen’s Novex system.  Membrane enriched protein was mixed 1:1 in 
a sample buffer that contained 106 mM Tris HCl, 141 mM Tris-base, 2% lithium dodecyl 
sulfate (LDS), 10% Glycerol, 0.51 mM EDTA, 0.075% Coomassie Blue R250 and 
0.025% phenol red, pH 8.5.  Nav are large proteins with 24 hydrophobic-rich 
transmembrane segments that can aggregate when exposed to high temperatures; 
therefore, protein was denatured at 37°C.  Protein used for Kv immunodetection was 
denatured at 70°C for 10 minutes.  20µg (Nav) or 40μg (Kv) of protein was loaded into 
the wells of a 4% Bis-Tris stacking gel.  Protein was separated electrophoretically 
through an 8% Bis-Tris resolving gel using a 3-N-morpholinopropanesulfonic acid 
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(MOPS)-SDS buffer, pH 7.7 supplemented with 5mM sodium bisulfite at 200 V.  
Following electrophoresis, proteins were transferred to nitrocellulose membranes (Nav) 
(GE Healthcare RPN3032D) or polyvinylidene fluoride (Kv) (PVDF: Millipore 
IPVH00010)  using a tank transfer system (Bio-Rad 170-3930) at 4° C for 2 hour at 50 V.  
The transfer solution consisted of Bis-Tris 25mM, bicine 25mM, EDTA 1mM, sodium 
bisulfite 5 mM, 20% methanol and 0.0375% SDS.  Blots were rinsed briefly then dried at 
room temperature and either used immediately or stored at 4°C.   
 Following western blotting, Nav and Kv visualization was performed using 
Millipore’s SNAP ID system following the manufacturer’s recommendations.  
Membranes were blocked with 0.5% non-fat dairy milk.  A pan-Nav antibody, which was 
described previously[178, 248], was used as the primary antibody and a goat anti-rabbit 
horseradish- peroxidase (HRP) conjugated antibody (Millipore AP307P) was used as the 
secondary.  The following table describes the commercially available antibodies used to 
detect the various Kv isoforms.   
Table 2.2: Antibodies used for Kv detection 
Kv Isoform Manufacturer Part Number Secondary 
Kv4.2 Upstate 07-491 Goat anti-rabbit HRP (Millipore 
AP307P) 
Kv1.5 Alomone APC-004 Goat anti-rabbit HRP (Millipore 
AP307P) 
Kv2.1 Neuromab 75-014 Goat anti-mouse HRP (Millipore 
AP308P) 
 
Nav and Kv protein levels were normalized to Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) protein expression using a mouse monoclonal antibody raised 
against GAPDH (Santa Cruz SC32233) as the primary and a HRP conjugated goat anti-
mouse antibody as the secondary (Millipore AP308P).  Blots were incubated with a 
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chemiluminescent substrate following the manufacturer's recommendations (Pierce 
34080).  A Tris buffered solution (TBST) consisting of 50 mM Tris, 0.154 mM NaCl and 
0.1% tween, pH 7.5 was used as the diluent and wash solution for the immunodetection 
protocol.  Following the chemiluminescent reaction, bands were visualized with 
autoradiography film (Midsci BX57), scanned and densitometry was performed using the 
National Institute of Health's ImageJ software application.   
 
2.12. Gel-shift analysis 
 Sarcolemmal protein was enriched and isolated as described above.  
Approximately 25 µg of protein was diluted to 10 µl with 20 mM Tris-base (pH 7.5) 
along with 0.5% LDS, 2X HALT protease inhibitor cocktail (Pierce 87785) and either 1 
U/ml of sialidase A (Prozyme GK80040) or a equal volume of 20 mM Tris-base/25 mM 
NaCl.  The solution was incubated for 2 hours at 37° C.  Following incubation, the 
solution was mixed 1:1 with a Lammeli-style sample buffer consisting of 62.5 mM Tris-
base pH 6.8, 25% glycerol, 2% LDS, 0.01% bromomethyl blue and 5% β-
mercaptoethanol and denatured at 37°C.  Denatured protein was added to a 4.5% 
Tris/glycine gel and separated electrophoretically as previously described[178].  Gels 
where then blotted onto nitrocellulose membranes using a semi-dry transfer apparatus 
(Bio-Rad 170-3940) at 15 V for 26 minutes in a transfer buffer consisting of Tris-base 48 
mM, glycine 39 mM, 20% methanol and 0.0375% SDS.  Following transfer, blots were 
rinsed briefly and allowed to air dry at room temperature.  To determine differences in 
apparent molecular weight (MW), scanned film was analyzed using ImageJ.  The log of 
each MW marker was plotted versus its distance in arbitrary units traveled into the gel.  A 
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linear regression was then performed and used to calculate the MW of sialidase-treated 
and untreated protein. 
 
2.13. Statistical analyses 
Data was analyzed with excel, clampfit and Sigmaplot 11.0 where appropriate.  
Reported values are the mean ± SEM.  Student’s t-test and one-way ANOVA with the 
Holms-Sidak method was used to determine statistical significance were appropriate.  
Mann-Whitney rank sum test was used when values were not normally distributed   p 
values are reported as calculated but were considered significant when less than 0.05.  
For electrophysiological measurements, sample numbers (n) are reported as the number 
of cells.  For all groups, cells originated from 4-6 different animals. 
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Chapter 3 
Results 
 
3.1. Introduction 
 The sequential glycosylation process typically ends with negatively charged sialic 
acid residues added through trans-Golgi sialyltransferase activity[153, 157].  
Sialytransferases are a group of 20 enzymes with unique substrate specificities, which 
include both glycoproteins and glycolipids[153].  Sialyltransferases belong to a much 
larger group of glycogene products that number in the hundreds responsible for creating a 
complex and variable glycan profile (glycome) unique to different cell types and 
tissues[177].  Sialic acid impacts Nav and Kv function and developmentally regulated 
sialylation contributes to cardiac myocyte excitability in the neonatal mouse atria[249, 
250].  However, little is understood concerning how the glycosylation machinery 
(glycogene products) influences cell and tissue electrical signaling.  The sialytransferase 
β-galactoside α-2,3-sialyltransferase 4 (ST3Gal4) adds sialic acids to galactose residues 
through an α-2,3-linkgage to core N- or O-linked glycans[153, 177, 230].  ST3Gal4 is 
uniformly expressed throughout the chambers and developmental stages of the heart and 
therefore is likely a useful target to question whether and how glycosylation impacts 
these events[177].  Additionally, diseases of glycosylation often cause symptoms that are 
consistent with changes in excitability that include arrhythmias and seizures[165, 215, 
216, 251, 252].  Diseases that affect glycosylation, such as CDG, do so variably 
throughout the glycosylation process; however, sialic acids are typically the terminal 
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residues of glycan structures therefore truncated glycans, as a result of pathological 
glycosylation, will often result in fewer sialic acids added.  In addition, Chagas disease, 
which results in pathological changes to cardiac electrical signaling, may reduce sialic 
acids directly[218-223, 253].  Because of this, the ST3Gal4
-/-
 strain was also used to 
investigate the role of glycosylation in the pathological cardiac electrical remodeling 
often associated with these diseases.  The methodologies included cellular, tissue and 
whole-animal electrophysiology as well as biochemical assays.  The data indicate that 
deletion of a single sialyltransferase, ST3Gal4, significantly affects Nav sialylation and 
gating with no change in maximum current density or protein expression.  ST3Gal4 
deletion also depolarizes the activation gating of both voltage-dependent kinetic 
components of repolarization found in the mouse ventricle: Ito and IKslow; however unlike 
the effect on INa, ST3Gal4 gene deletion causes a reduction in the peak IK density.  
Protein expression of the putative Kv isoforms responsible for Ito and IKslow was variably 
affected by ST3Gal4 gene deletion with Kv1.5 and Kv4.2 demonstrating no differences in 
protein densities.  Contrastingly, a small but significant reduction in Kv2.1 protein from 
ST3Gal4
-/-
 ventricular tissue was observed.  ST3Gal4 expression is necessary for normal 
cellular electrical signaling as demonstrated by a reduction in cellular refractory period 
and alterations in AP waveforms that include a slowing of cellular conduction and an 
extension of AP duration in ventricular myocytes from ST3Gal4
-/-
 mice.  Concurrent with 
aberrant excitability at the cellular level, the ST3Gal4
-/-
 left ventricular epicardium 
demonstrated a reduced refractory period and was more susceptible to arrhythmias as 
observed through optical mapping studies.  Additionally, ECGs of ambulatory ST3Gal4
-/-
 
mice demonstrated that deletion of the gene causes modest aberrant conduction under 
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basal conditions and, in preliminary studies, appears to increase the susceptibility to 
arrhythmogenesis following a cardiac challenge, in the form of a low dosage of the β-
adrenergic agonist isoproterenol, suggesting a reduction in repolarization reserve in the 
ST3Gal4 heart.  Based on the data reported here, it is apparent that relatively minor 
perturbations in the cardiac glycome cause significant changes in cardiac electrical 
signaling.  These data highlight the role of glycosylation in normal physiology and 
underscore it as an important mediator in diseases where it may be altered.   
 
3.2. Deletion of ST3Gal4
 
alters Nav gating but has no effect on maximum current 
density 
To determine the effect of gene deletion of the sialyltransferase ST3Gal4 on 
cardiac INa, the whole-cell patch-clamp recoding technique was performed on adult LVA 
myocytes isolated from WT and ST3Gal4
-/-
 mice.  At relatively small depolarizations, 
current densities were smaller in ST3Gal4
-/-
 myocytes compared to WT myocytes with no 
effect observed at greater depolarizations (Fig. 3.1B), suggesting that Nav gate differently 
with ST3Gal4 expression.  Mean cell capacitances for the two groups were similar (Table 
3.1).  G-V relationships were measured to determine the voltage-dependence of steady-
state activation (Fig. 3.2A).  The INa G-V relationships recorded from ST3Gal4
-/- 
myocytes were more depolarized than those from WT myocytes.  Boltzmann fits of the 
data showed a significant depolarizing shift of ~4 mV in Va for ST3Gal4
-/- 
Nav compared 
to WT controls with no difference in maximum conductance density between groups 
(Fig. 3.2B, Table 3.1).   
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Figure 3.1: ST3Gal4
-/-
 ventricular INa density is reduced at smaller depolarizations 
compared to WT controls but similar at more depolarized potentials.  Here and 
throughout unless noted, WT (Black circles/lines/bars; n=11) and ST3Gal4
-/- 
(Red 
diamonds/lines/bars; n=13).  Data are mean ± SEM.  A, Pulse protocol and representative 
whole myocyte INa traces.  Detailed pulse protocols are listed in the methods.  B, Current 
density-voltage relationships. *p≤0.032. 
 
Similarly, depolarizing shifts of ~4 mV in Vi (Fig. 3.3) and in SSI (Table 3.1) were also 
observed in ST3Gal4
-/- 
myocytes compared to WT controls, indicating that both voltage-
dependent events required a greater depolarization to occur and were similarly affected 
by ST3Gal4 gene deletion.  There were no differences in the slopes of the Boltzmann fits 
for G-V or SSI curves (Table 3.1), indicating that ST3Gal4 expression does not modulate 
the magnitude of charge translocation and/or stability of intermediate states during 
voltage-dependent Nav gating.  In additional studies, isolated LVA myocytes from WT 
mice were treated with sialidase A (50 mU/ml, 2-3 hours, 22 ± 1°C) to remove surface 
sialic acid residues.  Similar depolarizing shifts of ~4 mV in Va (n=10; p<0.001) and 3 
mV in Vi (n=10; p=0.031) were observed verifying that the changes in ST3Gal4
-/-
 Nav 
gating were consistent with a reduction in Nav sialylation.  
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Figure 3.2: ST3Gal4
-/-
 Nav activation gating is shifted to more depolarized potentials 
with no change in maximum conductance density.  A, Steady-state activation curves 
(conductance-voltage, GV relationships).  *p≤0.001.  Lines are best fits of the data to 
single Boltzmann function.  B, Bar graphs of maximal conductance density.  Maximal 
conductance for each cell was determined by best fits of G-V data for each cell.  
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Figure 3.3: ST3Gal4
-/-
 Nav inactivation gating is shifted to more depolarized 
potentials.  Steady-state inactivation curves.  *p≤0.007.  Lines are best fits of the data to 
single Boltzmann functions.  Insets: Steady-state inactivation pulse protocol and 
representative current traces.  
 
To test whether the observed rightward shift in Va corresponded with a slowing of 
fast inactivation, the decaying portion of each current trace was fit with a single 
exponential function.  At relatively small depolarizations, the time constants of fast 
inactivation (inact) were significantly longer in ST3Gal4
-/-
 myocytes compared to WT 
myocytes (Fig. 3.4, Table 3.1).  At further depolarizations, no statistically significant 
differences in inact were apparent indicating that the impact of ST3Gal4 expression on 
fast inactivation was likely mediated through a voltage-dependent process. 
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Figure 3.4.  Fast inactivation of Nav is slowed in ST3Gal4
-/-
 myocytes.  Time constants 
of fast inactivation (inact).  *p≤0.015.  Lines are non-theoretical point-to-point.  Inset, 
typical fast inactivation following a depolarization to -50 mV from a -100 mV holding 
potential.  
 
Next, the rate of recovery from fast inactivation was determined using a standard 
twin pulse protocol.  At recovery potentials of -90 mV (Fig. 3.5A) and -100 mV (Fig. 
3.5B), the time constants for recovery from fast inactivation (rec) decreased by ~23% in 
the ST3Gal4
-/-
 myocytes compared to WT myocytes (Fig.3.5C, Table 3.1).  Attempts to 
measure the rate of recovery from inactivation at the normal resting membrane potential 
demonstrated little to no recovery in Nav.  This is likely due to the to the lower Na
+ 
concentration in the ECS, which was used to maintain adequate voltage and space clamp 
integrity.  However, previous studies have suggested that the effect of sialic acid on 
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recovery from fast inactivation is voltage-dependent and as the test potential becomes 
more depolarized the effect on recovery is increased[176, 178].  Based on this, it is likely 
that at the measured membrane potential of ~-79 mV (as described in a subsequent 
section), the effect on recovery should be of even larger magnitude.  
 
 
Figure 3.5: Nav recovery from fast inactivation is accelerated in ST3Gal4
-/-
 mice.  
Data are the mean ± SEM fraction of recovered channels as a function of time (n=7 - 10).  
Lines are non-theoretical, point-to-point.  A and B, Recovery from fast inactivation from 
a recovery potential of: A, -90 mV.  B, -100 mV.  Insets, representative recovery current 
traces.  C, Bar graph indicating the mean trec ± SEM at each holding potential. 
(*p≤0.002).   
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Table 3.1: The mean ± SEM INa gating parameter values.   
 
 
 
Cm, cell capacitance.  Gmax, maximum conductance.  Significance was determined using a two-tailed Student's t test comparing WT 
and ST3Gal4
-/-
 groups.  * p≤0.015. 
 
  
Group 
Cm 
pF 
GMax/Cm 
(S/F) 
Va 
(mV) 
Ka 
(mV) 
 
Vi 
(mV) 
Ki 
(mV) 

inact(-60) 
(ms) 

inact(-55) 
(ms) 

inact(-50) 
(ms) 

rec(-100) 
(ms) 

rec(-90) 
(ms) 
WT 
(n=11) 
177.3±15.5 1.1±0.1 -52.4±0.6 5.6±0.3 -90.8±1.1 -6.5±0.3 9.0±0.6 4.7±0.3 3.1±0.1 24.0±0.9 69.7±1.4 
ST3Gal4
-/-
(n=13) 
161.4± 9.3 1.1±0.1 -48.5±0.6* 6.0±0.3 -87.2±0.7* -6.1±0.3 13.5±0.9* 7.3±0.6* 3.9±0.3* 18.6±1.2* 53.9±2.2* 
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3.3. Nav protein levels are unaltered but ST3Gal4
-/- 
ventricular Nav are less sialylated  
Western blot analysis of sarcolemmal-enriched protein was used to determine 
potential differences in Nav expression patterns between WT and ST3Gal4
-/-
 ventricular 
tissue.  Figure 3.6A depicts a representative blot probed with a pan-Nav polyclonal 
antibody.  Optical density of Nav bands in arbitrary units (AU) were determined and 
compared to GAPDH AU (8 samples/4 hearts per group), with no difference in Nav 
protein expression between ST3Gal4
-/- 
and WT ventricular tissue detected (Fig. 3.6B).  
Additionally no difference in GAPDH expression was observed (data not shown).  These 
data, along with the current density and maximum conductance data (Figs. 3.1B and 
3.2B), indicate that expression of ST3Gal4 does not confer any significant change in Nav 
surface expression or stability.  In the majority of blots, it was apparent that Nav protein 
isolated from WT ventricular tissue was of higher apparent molecular weight (MW) than 
ST3Gal4
-/-
 Nav protein.  As previously reported, a decrease in MW of ST3Gal4
-/-
 Nav 
protein is consistent with less sialylated Nav[177, 178].  To test this, protein from both 
groups was treated with sialidase A (Fig. 3.7).  Compared to WT Nav, untreated Nav 
protein from ST3Gal4
-/-
 ventricular tissue migrated farther, consistent with a 5.5 ± 1.6 kD 
shift (Fig. 3.7; n=7; *p<0.001).  Following sialidase treatment, the measured MW from 
both groups was reduced to nearly identical levels.  However, compared to their 
respective untreated proteins, sialidase-treated WT protein shifted approximately 10.1 ± 
0.7 kD while sialidase-treated ST3Gal4
-/- 
protein shifted approximately 5.3 ± 1.2 kD.  
These data suggest that Nav from ST3Gal4
-/- 
ventricular tissue are sialylated but likely 
have fewer sialic acid residues attached than WT channels. 
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Figure 3.6: Nav protein expression is similar in ST3Gal4
-/-
 ventricular tissue 
compared to WT control.  A, Representative western blot of sarcolemmal enriched Nav 
protein (left panel) and GAPDH (right panel) taken from WT and ST3Gal4
-/-
 ventricular 
tissue.  B, Bar graph demonstrating no difference in Nav protein expression in ST3Gal4
-/- 
compared to WT ventricles.  
 
 
 
 
 
 
 
Figure 3.7: ST3Gal4
-/-
 Nav protein is of lower apparent molecular weight and is less 
sensitive to desialylation than WT.  Gel-shift analysis: Sarcolemmal enriched protein 
was treated with sialidase A.  Data suggest that ST3Gal4
-/-
 Nav protein (solid black line) 
is of lower MW than WT Nav protein (solid red line).  The measured MW from WT and 
ST3Gal4
-/-
 protein were nearly identical following enzymatic desialylation, but WT 
protein (dashed black line) demonstrates a greater MW shift than ST3Gal4
-/-
 protein 
(dashed red line).  The mean ± SEM MW shifts for each sample compared to untreated 
WT protein is listed at the bottom of the blot (n=7; *p<0.001).   
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3.4. Cellular refractory period is shorter in ST3Gal4
-/- 
LVA myocytes 
  Nav recovery from fast inactivation plays a pivotal role in refractory period and in 
cardiac conduction.  To test whether the observed differences in Nav recovery in 
ST3Gal4
-/-
 myocytes lead to differences in cellular refractory period, current-clamp 
experiments were performed on LVA myocytes isolated from ST3Gal4
-/- 
and WT mice 
(Fig. 3.8).  EGTA was omitted from the ICS in order to better simulate normal myocyte 
electrical signaling where Ca
2+
 would contribute.  There were no significant differences 
between the mean ST3Gal4
-/-
 and WT control resting membrane potentials (ST3Gal4
-/-
 = 
-79.7 ± 0.8 mV; WT = -79.9 ± 1.1 mV, p=0.9) or the threshold of AP firing (ST3Gal4
-/-
 = 
538.7 ± 43.9 picoamps; WT = 524.5 ±50.8 picoamps, p=0.8).  However, concurrent with 
an acceleration in Nav recovery from fast inactivation, the cellular refractory period was 
significantly shorter in ST3Gal4
-/-
 LVA myocytes by approximately 30 ms (139.8 ± 8.6 
ms for WT n=13 and 110.2 ± 10.0 ms for ST3Gal4
-/- 
n=13; p=0.035; (Fig. 3.8A and B). 
 
3.5. ST3Gal4 gene deletion affects repolarizing K
+
 currents 
 Repolarization in adult mouse ventricular myocytes occurs primarily through the 
action of three kinetically distinct K
+
 current types: Ito, IKslow and ISS.  Ito and IKslow (Fig. 
3.9) are thought to be conducted through a combination of at least three putative Kv 
isoforms.  Studies using transgenic mice describe that Kv4.2 is necessary for Ito; however, 
there is biochemical and molecular evidence that Kv4.3 may tetramerize with it[31, 193, 
254-256].  Similar studies showed that Kv1.5 and Kv2.1 both contribute to IKslow[257, 
258].   
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Figure 3.8: ST3Gal4
-/-
 myocyte refractory period is significantly shorter than WT.   
Action potentials were recorded in current-clamp mode and cellular refractory period was 
estimated as described (n=13).  A, Representative voltage traces of WT and ST3Gal4
-/-
 
action potentials superimposed from independent experiments to demonstrate the 
shortened refractory period in ST3Gal4
-/- 
myocytes.  B, Bar graph of cellular refractory 
period in ms: WT (139.8 ± 8.6) and ST3Gal4
-/-
 (110.2 ± 10.0); *p=0.035. 
 
 
The molecular component(s) of ISS is still under debate with evidence suggesting a role 
for member(s) of a two-pore domain K
+ 
channel family, which do not exhibit any 
appreciable voltage-dependence[259-262].  This can confound investigations into the 
effect of a model system designed to test the role of each contributing K
+
 channel 
isoform.  One work-around that was developed and validated was to separate the kinetic 
components graphically or mathematically by fitting the decaying portion of each current 
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trace with a bi-exponential function (see methods)[31, 43, 78, 263, 264].  Here, this 
method was employed to assess the role of ST3Gal4 in repolarizing K
+ 
channel activity, 
with a focus on Kv, in LVA myocytes using the whole-cell voltage-clamp recording 
technique (Fig. 3.9).   
 Peak outward IK density recorded from ST3Gal4
-/-
 myocytes was significantly 
smaller at all depolarized membrane potentials from -20 mV to 50 mV (Fig. 3.10A).  The 
currents were then separated based on each contributing kinetic component [the rapidly 
inactivating (Ito), the slowly inactivating (IKslow) and non-inactivating (ISS)].   
 
 
Figure 3.9: Representative voltage-sensitive outward K
+
 currents.  Current traces 
demonstrating the different kinetic portions of mouse ventricular voltage-sensitive 
outward K
+
 currents, which consist of rapidly inactivating, slowly inactivating and non-
inactivating components (Ito, IKslow and ISS respectively).  Insets include the putative 
molecular correlates, representative current traces from recordings performed using 
heterologously expressed channel clones for each correlate, the effects of desialylation 
from those same expression system studies and the voltage pulse protocol.  The 
expression system data are from Schwetz et al.[195, 196].  
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ST3Gal4
-/-
 Ito and IKslow demonstrated decreased current densities at smaller, non-
saturating membrane potentials compared to WT (Fig. 3.10B and C).  Conversely, 
ST3Gal4
-/-
 ISS density was smaller at more depolarized membrane potentials (30 to 50 
mV) compared to WT controls (Fig. 3.10D).  Cell capacitances were similar for both 
groups (Table 3.2).  
 
 
Figure 3.10: ST3Gal4
-/-
 ventricular IK is altered compared to WT controls.  Here and 
throughout unless noted, WT (Black circles/lines/bars; n=10) and ST3Gal4
-/- 
(Red 
diamonds/lines/bars; n=10).  Data are mean ± SEM.  A, Peak outward IK density is 
reduced at all depolarized membrane potentials in ST3Gal4
-/-
.  B, ST3Gal4
-/-
 Ito density is 
reduced at smaller depolarizing potentials but similar at more depolarized ones.  B, 
ST3Gal4
-/-
 IKslow density is reduced at smaller depolarizing potentials but similar at more 
depolarized ones.  D, ST3Gal4
-/-
 ISS density is reduced at saturating membrane potentials.  
Each kinetic component was derived by fitting the attenuating portion of each current 
trace with a bi-exponential function as described in the methods. *p≤0.05.  
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 The significant reduction in current density at small, but not large depolarizations, 
suggests that ST3Gal4 gene deletion modulates Ito and IKslow gating.  G-V relationships 
were measured to determine the voltage-dependence of steady-state activation for Ito and 
IKslow (Figs. 3.11A and 3.12A).  ISS conductance was not accurately described by a 
Boltzmann relationship.  The G-V relationships of Ito and IKslow from ST3Gal4
-/- 
myocytes 
were more depolarized than those from WT myocytes.  Boltzmann fits of the data 
showed significant depolarizing shifts in Va of ~8 mV for Ito and 7 mV for IKslow from 
ST3Gal4
-/- 
myocytes compared to WT controls with no significant differences in maximal 
conductance densities between groups for either current types (Figs. 3.11B and 3.12B, 
Table 3.2).  There was a small but significant broadening of the Boltzmann slopes from 
the G-V relationships for ST3Gal4
-/-
 Ito and IKslow compared to WT controls of 
approximately 2 and 1.5 mV respectively (Table 3.2).  SSI of Ito was well fit by a single 
Boltzmann function and was not different between the two groups.  IKslow, however, was 
better fit by the sum of two Boltzmann relationships (see methods).  IKslow SSI 
relationships were also not different between WT and ST3Gal4
-/-
 myocytes (Fig. 3.13A 
and B and Table 3.2).   
 Experiments were performed with Sialidase A as described in section 3.2 above.  
Results from these studies demonstrated that enzymatic removal of surface sialic acids 
caused similar differences in Ito and IKslow activation gating with significant ~7 and ~5 mV 
shifts in Va, respectively, compared to untreated WT myocytes (sialidase treated: n=6; 
WT: n=10; p≤0.007).  These data, like those for INa, indicate that the observed effect of 
ST3Gal4 gene deletion on IK is consistent with a reduction in surface sialic acids.  
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Figure 3.11: ST3Gal4
-/-
 Ito gating is shifted to more depolarized potentials with no 
change in maximum conductance density.  A, Steady-state activation curves of Ito 
(conductance-voltage, GV relationships).  B, Bar graphs of maximal conductance density.  
Maximal conductance for each cell was determined by best fits of G-V data for each cell.  
*p≤0.031.  Lines are best fits of the data to single Boltzmann functions.  
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Figure 3.12: ST3Gal4
-/-
 IKslow gating is shifted to more depolarized potentials with no 
change in maximum conductance density.  A, Steady-state activation curves of IKslow 
(conductance-voltage, GV relationships).  B, Bar graphs of maximal conductance density.  
Maximal conductance for each cell was determined by best fits of G-V data for each cell.  
*p≤0.031.  Lines are best fits of the data to single Boltzmann functions.   
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Figure 3.13: ST3Gal4
 
expression does not affect Ito and IKslow SSI gating.  A, Ito SSI 
curves describe no difference in inactivation gating.  B, ST3Gal4
-/-
 IKslow SSI curves 
describe no difference in inactivation gating.  Lines are best fits of the data to single (Ito) 
or double (Ikslow) Boltzmann functions. C, Representative current traces and pulse 
protocol for SSI.   
 
 
 The rates of inactivation were determined through fitting the decaying portion of 
each current trace with a bi-exponential function (see methods).  The inact for Ito was not 
different at any membrane potential for the two groups (Fig 3.14A and B); however, the 
inact for IKslow was significantly slower in the ST3Gal4
-/-
 myocytes at most depolarized 
potentials (Fig. 3.14A and C). 
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Table 3.2: The mean ± SEM IK gating parameter values 
 
 
 
Cm 
pF 
Ito IKslow 
Gmax/Cm 
(S/F) 
Va 
(mV) 
Ka 
(mV) 
Vi 
(mV) 
Ki 
(mV) 
Gmax/Cap 
(S/F) 
Va 
(mV) 
Ka 
(mV) 
Vi1 
(mV) 
Ki1 
(mV) 
Vi2 
(mV) 
Ki2 
(mV) 
WT 
N=10 
163.3 
± 
11.1 
0.18 
± 
0.03 
-3.1 
± 
1.1 
11.7 
± 
0.7 
-38.6 
± 
1.1 
-4.2 
± 
0.5 
0.11 
± 
0.01 
-16.7 
± 
0.8 
7.6 
± 
0.3 
-84.1 
± 
1.0 
-9.9 
± 
2.6 
-35.1 
± 
1.2 
-4.1 
± 
0.3 
ST3Gal4
-/- 
N=10 
174.3 
± 
20.3 
0.13 
± 
0.02 
4.7 
± 
1.9* 
13.9 
± 
0.4* 
-37.3 
± 
0.6 
-5.3 
± 
0.8 
0.09 
± 
0.02 
-9.9 
± 
0.9* 
9.0 
± 
0.6* 
-84.9 
± 
2.3 
-7.9 
± 
2.0 
-34.1 
± 
2.1 
-5.9 
± 
0.4* 
 
Cm, cell capacitance.  Gmax, maximum conductance.  Significance was determined using a two-tailed Student's t test or Mann-Whitney 
rank sums comparing WT and ST3Gal4
-/-
 groups.  * p≤0.034. 
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Figure 3.14: Ito inactivation kinetics are similar in ST3Gal4
-/-
 myocytes but IKslow 
inactivation kinetics are slowed compared to WT myocytes.  A, Representative 
current traces from WT (black) and ST3Gal4
-/-
 (red) illustrating similar Ito inactivation 
kinetics but a slower rate of inactivation for IKslow.  B, Ito time constants of inactivation 
(tinact).  C, IKslow  tinact.    *p≤0.025.  Lines are non-theoretical point-to-point.  
  
 In addition to being distinct kinetically, the various Kv isoforms that are expressed 
in mouse ventricular myocytes have varying sensitivities to pharmacological agents.  For 
example Kv1.5 is preferentially blocked by micromolar (μM) concentrations of 4-
aminopyridine (4AP) and Kv2.1 by mM concentrations of tetraethyl ammonium 
(TEA)[265].  Experiments were performed to gain insight into which Kv isoforms were 
affected by ST3Gal4 gene deletion.  Table 5 describes the effects of 50 μM 4AP and 5 
mM TEA (included in the ECS while recording from WT and ST3Gal4
-/-
 LVA myocytes) 
on Ito and IKslow activation gating and inact.  Conductance voltage relationships and inact 
were determined as described in the methods. 
4321
Time (s) Sw eep:9 Visible:1 of 11
Im (p
A)
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
1342
Membrane Potential
-20 -10 0 10 20 30 40 50
in
a
ct
 m
s
600
800
1000
1200
1400
WT 
ST3Gal4
-/-
 
*
* *
*
*IKslow tinact
A
Membrane Potential mV
-20 -10 0 10 20 30 40 50
in
a
ct
 m
s
60
80
100
120
140
WT 
ST3Gal4
-/-
 
Ito tinact
CB
5
0
0
 p
A
200 ms
83 
 
Table 3.3: Activation gating and inact for Ito and IKslow with 4AP and TEA  
Group 
Ito 50μM 4AP IKslow50μM 4AP 
Va 
(mV) 
Ka 
(mV) 
inact 30 mV 
(ms) 
Va 
(mV) 
Ka 
(mV) 
inact 30 mV 
(ms) 
WT 
N=8 
9.3±0.7
$ 
11.6±0.4 35.3±1.7
$ 
-1.5±0.9
$ 
6.3±0.2
$ 
1898.5±84.1
$ 
ST3Gal4
-/-
 
N=7 
10.1±1.7 12.7±0.8 39.6±3.5 1.5±0.4* 6.9±0.3 1744.9±87.3 
Group 
Ito 5mM TEA IKslow 5mM TEA 
Va 
(mV) 
Ka 
(mV) 
inact(30 mV) 
(ms) 
Va 
(mV) 
Ka 
(mV) 
inact(30 mV) 
(ms) 
WT 
N=7 
-3.3±1.5 11.8±0.3 52.4±3.5 -15.3±0.6 8.1±0.3 783.2±44.7
& 
ST3Gal4
-/-
 
N=8 
3.9±1.1* 12.7±0.5 51.7±3.5 -13.9±0.9 7.9±0.3 808.3±27.5 
Group 
Ito Untreated IKslow Untreated 
Va 
(mV) 
Ka 
(mV) 
inact(30 mV) 
(ms) 
Va 
(mV) 
Ka 
(mV) 
inact(30 mV) 
(ms) 
WT 
N=10 
-3.1±1.1 11.7±0.7 58.4±4.6
 
-16.7±0.8 7.6±0.3 995.0±20.7
 
ST3Gal4
-/-
 
N=10 
4.7±1.9
# 
13.9±0.4
# 
61.0±5.3 -9.9±0.9
# 
9.0±0.6
# 
1195.9±53.6
# 
Significance was determined using a two-tailed Student's t test or Mann-Whitney rank 
sum test.  *p≤0.012 comparing treated myocytes.  #p≤0.034 comparing untreated 
myocytes.  
$
p≤0.004 comparing 4-AP treated WT myocytes to WT myocytes.  &p<0.001 
comparing TEA treated WT myocytes to WT myocytes. 
 
Evidenced by the relative shifts in Va, the data suggest that Kv1.5 and Kv2.1 are affected 
by ST3Gal4 gene deletion but Kv4.2 is not (Fig. 3.15 and Table 3.1).  In the presence of 
50 μM 4AP (which preferentially blocks Kv1.5) there is no apparent effect on Ito 
activation.  Contrastingly, when 5 mM TEA (which blocks Kv2.1) is used there is no 
observed shift in IKslow Va but the effect on Ito remains.  Interestingly, based on these data, 
it would appear as though Kv1.5 contributes to both Ito and IKslow.  This is supported by a 
number of factors: 1) when Kv1.5 is blocked (50 μM 4AP) the Va for Ito is depolarized by 
~15 mV compared to the untreated WT Va (Fig. 3.15A and Table 3.4) and 2) in the 
presence of 4AP, WT inact becomes significantly faster compared to untreated WT inact at 
30 mV [~35 ms (WT + 50 μM 4AP; n=8) versus ~58 ms (WT untreated; n=10; p<0.001; 
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Table 5)].  In the presence of 5 mM TEA, the inact for Ito is statistically the same as 
untreated WT inact, at 30 mV (Table 3.4).  Additionally, when Kv1.5 is blocked with 
4AP, the inact for IKslow is significantly slower and when Kv2.1 is blocked with TEA, inact 
for IKslow is accelerated, both compared to untreated WT myocytes at 30 mV (Table 3.4).   
 
  
Figure 3.15: Pharmacological treatment of myocytes suggests that activation gating 
of Kv1.5 and Kv2.1 are affected by ST3Gal4 expression but Kv4.2 is not.  G-V curves 
of Ito and IKslow comparing untreated myocytes (dashed lines, black and red) and 
myocytes treated with 50 µM 4-AP (A and B), which preferentially blocks Kv1.5, and 5 
mM TEA (C and D), which preferentially blocks Kv2.1 (solid lines, blue and green).  A, 
The effect of ST3Gal4 gene deletion on Ito activation gating is removed following 4-AP 
treatment suggesting that Kv4.2 is not affected by ST3Gal4 expression but that Kv1.5 is 
and that it contributes to Ito.  B, In the presence of 4-AP, IKslow activation gating is 
depolarized by ~3 mV suggesting that Kv2.1 is affected by ST3Gal4 expression.  C, Ito 
activation gating is indistinguishable between groups following 5 mM TEA treatment.  D, 
In the presence of 5 mM TEA, the depolarizing effect of ST3Gal4 expression on IKslow Va 
is removed supporting the idea that Kv2.1 is affected by ST3Gal4 expression.  * p≤0.029. 
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Point 1 is supported by studies using heterologously expressed channel isoform 
constructs that demonstrate a less depolarized Va for Kv1.5 compared to Kv4.2[195, 196].  
Therefore, Kv1.5 may cause Ito in the mouse ventricle to also gate at less depolarized 
membrane potentials as evidenced by the above mentioned data.  These findings, 
however, are not conclusive and may simply be an artifact of the method employed to 
delineate the current types.  In mouse myocytes, Kv isoforms associate with a number of 
accessory subunits that can confer changes in activity.  The studies mentioned comparing 
the Va of Kv1.5 and Kv4.2 were done so without the co-expression of any auxiliary 
subunits.  Additionally, pharmacological treatment of myocytes, which express an array 
of different ion channels that may be unknowingly affected by different chemical agents, 
can cause significantly confounding results including state dependent block of a number 
of isoforms (including Kv4.2) that may alter channel activity[266, 267].  Moreover, 
external TEA was shown to alter the inactivation of Kv1.5, which could lessen the 
effectiveness of the methodology employed to delineate the current types[268].  There 
were also no differences in the slopes of the Boltzmann fits in the presence of 4AP or 
TEA compared to the slight broadening observed in ST3Gal4
-/-
 myocytes without 
treatment.  This may be a result of incomplete block or state-dependent block of the 
channels. 
Together the data describe that deletion of ST3Gal4, which would likely lead to a 
decrease in protein sialylation including potentially Kv, causes relative, depolarizing shifts 
in activation gating of the two kinetic components of voltage-sensitive K
+ 
current in the 
mouse ventricle: Ito and IKslow.  This likely involves some combination of the Kv isoforms 
4.2, 1.5 and 2.1 as described above.  This phenomenon is consistent with studies 
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mentioned in the introduction on the effect of desialylation of Kv in expression system 
studies; however, because there are multiple channel types active in cardiac myocytes 
during the IK voltage-clamp protocols, the methodology employed here can only provide 
a suggestion as to how the channels are affected.  Peak IK density was smaller in 
ST3Gal4
-/- 
myocytes.  This was likely caused by the combination of the decrease in 
current densities at non-saturating membrane potentials for Ito and IKslow, which can be 
ascribed to the observed differences in G-V relationships for the two current types, and 
the decrease in ISS observed at more depolarized potentials.  Additionally, while not 
conclusive, the pharmacological data with 4AP and TEA suggest there may be an isoform 
specific effect of ST3Gal4
 
deletion where Kv1.5 and Kv2.1 gate differently but Kv4.2 
does not.  This supposition would benefit from additional studies, including different, 
more specific blockers or combinations of channel blockers; however, these data are 
consistent with studies describing the roles of isoform specific and regulated 
glycosylation/sialylation in VGIC function.  The latter may be of specific relevance when 
considering that ST3Gal4
 
is only 1 of 20 sialyltransferases (although not all sialylate 
glycoproteins) and therefore may not contribute equally to the sialylation of all Kv 
expressed in the mouse ventricle. 
 
3.6. Kv isoform protein levels are differentially affected by ST3Gal4
 
gene deletion 
 Western blot analysis of sarcolemmal-enriched protein was used to determine 
potential differences in expression of the various Kv isoforms between WT and ST3Gal4
-
/-
 ventricular tissue.  Figure 3.16 depicts representative blots probed with antibodies 
specific for the three major Kv isoforms present in mouse ventricles (Table 2.2).  Optical 
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densities of the protein bands were reported in AUs as described above and in the 
methods section and compared to GAPDH AUs from the corresponding blots (5-13 
samples/ 4-6 hearts per group).  There were no differences in the protein densities of 
Kv4.2 or Kv1.5 between ST3Gal4
-/- 
and WT ventricular tissue detected (Fig. 3.16A and B.  
However, a small but significant ~20% reduction in Kv2.1 expression was detected (Fig. 
3.16A and B).  The data suggest that ST3Gal4 may contribute to the protein/surface 
expression of Kv2.1 but does not similarly affect Kv4.2 or Kv1.5.  An isoform specific 
effect of glycosylation on Kv trafficking and surface expression was previously 
reported[269]. 
 
Figure 3.16: ST3Gal4 gene deletion reduces Kv2.1 protein expression but not Kv4.2 
or Kv1.5.  A, Representative western blots of Kv4.2 (left), Kv1.5 (middle) and Kv2.1 
(right) along with corresponding GAPDH (bottom of each panel; ~35kD).  B, Bar graph 
comparing relative expression of the three Kv isoforms normalized to GAPDH expression 
from WT (black) and ST3Gal4
-/-
(red) ventricular tissue as described in the methods.  
Kv2.1 expression was reduced by ~21% in ST3Gal4
-/-
 ventricles with no observed change 
in Kv4.2 or Kv1.5.  Groups compared using Student’s t test (n=5-13, at least 4 hearts per 
group; *p<0.001. 
Kv4.2 Kv1.5 Kv2.1
K
v
 A
U
/G
A
P
D
H
 A
U
0.0
0.2
0.4
0.6
0.8
1.0
1.2
*
Kv4.2
WT ST3Gal4-/-
~ 75 kD
~ 35 kD
Kv1.5
WT ST3Gal4-/-
~ 75 kD
~ 35 kD
Kv2.1
WT ST3Gal4-/-
~ 35 kD
~ 100 kD
A
B
88 
 
Gel-shift analyses attempting to compare sialic acid levels on the three Kv 
isoforms between ST3Gal4
-/-
 and WT ventricles were unsuccessful.  Potentially, this was 
caused in part by the relatively low amounts of sialic acids likely found on the channels 
as will be discussed in more detail in a subsequent section.  However, pilot studies 
designed to quantify sialic acid levels using biochemical approaches were initiated.  The 
studies will attempt to exploit the reactivity of carbohydrates to oxidation by periodic 
acid using dissolved sodium periodate[270].  The oxidation reaction produces reactive 
aldehydes that are typically not present on proteins or the cell surface.  Sialic acids can be 
preferentially oxidized by performing the reaction at 4°C, in the dark and with a 
relatively lower sodium periodate concentration than if attempting to oxidize all 
carbohydrates[271, 272].  Following oxidation, newly formed sialic acid-aldehydes can 
be labeled with derivatized hydrazides or alkoxyamines through a nucleophilic reaction 
to form hydrazone or oxime bonded conjugates respectively[271, 272].  The derivatized 
functional groups can include biotin or various fluorophores, which then can be detected 
and quantified using protein electrophoresis or histochemical approaches.  Additionally, 
aniline can be used to catalyze the nucleophilic reaction increasing efficiency and 
allowing for the use of more physiological solutions[271].  This methodology can be 
employed to detect sialic acids on immunoprecipitated proteins as well as intact cells 
using cell-impermeant alkoxyamine/hydrazide molecules.  The latter being of particular 
interest to question whether and how sialic acids may be distributed across the cell 
membranes of cardiomyocytes.  Method develop using biochemical labeling approaches 
has begun and will be the focus of future experiments that are intended to investigate the 
quantity and distribution of sialic acid levels on proteins or the cell surface. 
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3.7. ST3Gal4 expression contributes to action potentials in mouse ventricular 
myocytes  
 Nav and Kv play crucial roles in generating and shaping the AP.  To determine 
how the observed differences in Nav and Kv activity in ST3Gal4
-/-
 myocytes would affect 
APs, whole-cell current-clamp experiments were performed.  In addition to INa and IK, 
Ca
2+ 
also contributes to shaping the AP via entry through Cav and release from 
intracellular stores.  In contrast to the cellular refractory period measurements discussed 
previously, EGTA was included in the AP ICS to chelate Ca
2+
.  This allows for the more 
accurate assessment of the roles of Nav and Kv activities throughout the AP.  Resting 
membrane potentials were similar between the two groups; however, a number of AP 
parameters were affected by ST3Gal4 gene deletion (Fig. 3.17; Table 3.4).  Among these 
were a longer time to AP peak, a delay in the time of the maximum rising slope and an 
extension of APD at 25, 50, 75 and 90% of repolarization.  There were no differences in 
the maximum slope of the rising portion of the AP or in the peak amplitude between 
groups. 
Table 3.4: Action Potential Parameters 
Group 
Rm 
mV 
125% 
Thresh 
pA 
TTP 
ms 
Max Slope 
V/S 
TMS 
ms 
APD25 
ms 
APD50 
ms 
APD75 
ms 
APD90 
ms 
WT 
N=8 
-71.1±0.9 736.3±35.8 10.5±0.3 103.6±14.8 9.9±0.2 9.1±0.5 11.6±1.0 16.4±1.9 25.8±3.0 
ST3Gal4
-/- 
N=9 
-69.7±0.7 586.3±63.6 12.3±0.5* 95.8±11.8 11.7±0.5* 11.1±0.6* 15.1±1.0* 21.8±1.5* 36.9±2.3* 
    Rm, resting membrane potential.  125% Thresh, 125% of the threshold current.  TTP, 
time to AP peak.  Max Slope, maximum rising portion of AP.  TMS, time of max slope.  
Significance was determined using a two-tailed Student's t comparing WT and ST3Gal4
-/-
 
groups.  p≤0.045. 
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Figure 3.17: Time to action potential peak and action potential duration are altered 
in ST3Gal4
-/-
 myocytes compared to WT controls.  A, Representative voltage traces 
from ST3Gal4
-/-
 (red) and WT (black) myocytes.  B, Bar graphs describing WT (black, 
n=9) and ST3Gal4
-/-
 (red, n=8) action potential parameters.  Rm, resting membrane 
potential.  Peak, maximum action potential amplitude.  TMS, time to reach the maximum 
rising slope.  TTP, time to peak of action potential.  APD, action potential duration at 25, 
50, 75 and 90% of repolarization.  *p≤0.045. 
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3.8. ST3Gal4
-/-
 hearts are more susceptible to ventricular arrhythmias 
 The measured decrease in ventricular myocyte refractory period and/or the 
alterations in AP waveforms (Figs. 3.8 and 3.17) could be pro-arrhythmogenic.  To 
question whether the ST3Gal4
-/-
 ventricles were more susceptible to aberrant conduction, 
we studied and compared conduction across the epicardium of ST3Gal4
-/- 
and WT left 
ventricles using optical mapping techniques as described.  The mean refractory period 
was a significant ~23 ms shorter for the ST3Gal4
-/-
 left ventricles compared to WT 
(ST3Gal4
-/-
, 59.5 ± 5.5 ms; WT, 82.4 ± 6.8 ms; n=11, p<0.01).  Conduction velocity was 
slightly, but insignificantly slower along the ST3Gal4
-/-
 epicardium (ST3Gal4
-/-
, 0.57 ± 
0.04 m/s; WT, 0.62 ± 0.03 m/s; p = 0.31).  Following determination of the refractory 
period, ventricles were stimulated with 2-6 suprathreshold 2 ms pulses at intervals 5 ms 
longer than the measured refractory periods (pacing protocol).  The stimulation protocol 
had little effect on WT conduction (Fig. 3.18A and C); only one WT ventricle displayed 
any type of aberrant conduction, a modest ventricular tachycardia (Fig. 3.18A and C).  
However, nearly 75% of the ST3Gal4
-/-
 hearts tested showed some significant aberrant 
conduction (Fig. 3.18A).  The observed arrhythmic behavior (Fig. 3.18B and C) included 
ventricular tachycardia (in 62.5% of arrhythmic ST3Gal4
-/-
 ventricles), reentry (25%), 
afterdepolarizations (12.5%), and ventricular fibrillation (25%).  In the ST3Gal4
-/-
 
ventricles, such arrhythmias were observed typically after only two or three pulses, while 
up to six stimulating pulses did not induce any type of arrhythmic behavior in 91% of 
WT ventricles tested.  Examples of the typical impact of the pacing protocol on WT and 
ST3Gal4
-/-
 ventricles are shown in Fig. 3.18C.  These data strongly suggest that the 
ST3Gal4
-/-
 ventricle is more susceptible to aberrant conduction.  This is consistent with 
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both the faster Nav channel recovery from fast inactivation that likely contributes to 
shorter cellular and epicardial refractory periods and the altered AP waveforms, including 
the extension of APD that may contribute to afterdepolarizations.   
 
3.9. Electrocardiograms from ST3Gal4
-/-
 hearts demonstrate a slowing of heart rate, 
aberrant conduction and suggest a reduction in repolarization reserve  
 To test whether the differences in channel function and cellular electrical 
signaling as well as the apparent increased susceptibility to arrhythmias in the left 
ventricular epicardium observed in ST3Gal4
-/- 
mice could affect cardiac conduction under 
normal physiological conditions, ECGs were recorded from conscious unrestrained 
animals.  Mean heart rates were significantly slower in ST3Gal4
-/-
 mice and displayed 
more variability.  Concurrent with this was a consistent lengthening and dispersion of the 
P wave and RR interval (Fig. 3.19A and B).  In addition to a slower heart rate, four of the 
nine ST3Gal4
-/-
 mice demonstrated aberrant conduction events that included premature 
ventricular contractions and irregular spacing between systoles (Fig. 3.19C).  None of the 
nine WT animals displayed any type of apparent conduction anomalies.   
 Because the heart can demonstrate significant conduction/repolarization 
reserve[273, 274], which can potentially mask variations in conduction under normal 
conditions of cardiac function, additional preliminary experiments were performed in an 
attempt to determine potential differences in response to a cardiac "challenge" between 
ST3Gal4
-/-
 and WT animals.   
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Figure 3.18.  ST3Gal4
-/-
 ventricles are more susceptible to arrhythmias.  Left 
ventricular conduction in WT and ST3Gal4
-/-
 hearts was studied using optical mapping 
methods as described (n=11). A, Percentage of ventricles displaying at least one type of 
arrhythmia.  The single WT (black) ventricle showing arrhythmic behavior displayed 
modest V. Tach.  B, Percentage of arrhythmic ST3Gal4
-/-
 ventricles presenting with one 
of four types of ventricular arrhythmias (see methods).  C, Representative data from a 
single WT (panels 1, 2) and ST3GAl4
-/-
 (panels 3, 4) heart.  1 and 3, Activity following 
two stimulating pulses at intervals ~2X the measured refractory period.  2 and 4, Activity 
following 5 (WT, panel 2), and 3 (ST3Gal4
-/-
, panel 4) stimulating pulses at intervals 5 
ms longer than the measured refractory period.  Figure generated by Jiashin Wu and used 
with permission.  Figure created by Jiashin Wu and used with permission. 
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Figure 3.19: Electrocardiograms from ST3Gal4
-/- 
and WT mice suggest altered 
cardiac conduction and rhythm.  A, 1 second sampling of ECGs recorded from two 
ST3Gal4
-/-
 mice (KO, black and blue, top two) and one WT mouse (control, green, 
bottom) demonstrate slowed heart rates in ST3Gal4
-/- 
mice.  B, enlarged view of P and 
QRS segments from the same mice.  The P and RR intervals are lengthened in the two 
ST3Gal4
-/-
 mice compared to WT controls.  C, Apparent premature beat observed in an 
ECG from a ST3Gal4
-/- 
mouse.  Such arrhythmias occurred consistently in ST3Gal4
-/-
 
mice but at irregular intervals.  Similar arrhythmic events were not observed in any WT 
mice. 
 
 
A low dosage (8mg/kg) of the β-adrenergic agonist isoproterenol, which demonstrates 
positive chronotropic and ionotropic effects on the heart[275], was administered 
intraperitoneally to ST3Gal4
-/-
(n=2) and WT (n=1) groups (Fig. 3.20).  Following 
administration of isoproterenol, both of the ST3Gal4
-/-
 animals demonstrated marked 
changes in ECG waveforms that began with early sinus bradycardia with ST elevation 
followed by ST depression and apparent QT prolongation.  A previous study utilized a 
similar dosage and too reported no effect on WT mice[276].  24 hours later the ECGs for 
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both groups were normal.  Isoproterenol was again administered and produced similar 
effects on both ST3Gal4
-/- 
animals whereas, again, did not affect the WT.  Following this 
second treatment, ECGs from the ST3Gal4
-/- 
mice only marginally recovered even after 
48 hours at which point the animals were euthanized.  The results obtained from the 
isoproterenol experiments suggest that ST3Gal4
-/-
 mice are more susceptible to β-
adrenergic stimulation that may be related to a reduction in repolarization reserve.  While 
extremely preliminary given the low sample numbers and the lack of specificity of 
isoproterenol treatments, these data are provocative and consistent with the observed 
differences in ST3Gal4
-/-
 Nav and Kv activity as well as the extension of APD that all may 
contribute to reduce repolarization reserve.  However, since the transgene is globally 
expressed, the data do not rule out a number of other possible explanations for the 
heightened response to isoproterenol that may include aberrant autonomic innervation, a 
potentiated effect on nodal cells or an increased sensitivity to isoproterenol by β-
adrenergic receptors in the ST3Gal4
-/-
 mice.  There is evidence that adrenergic receptors 
are sialylated and that sialic acids may influence the binding of certain 
agonists/antagonists[277-279].  Additionally, isoproterenol may acerbate any potential 
differences in neuronal regulation of the heart caused by ST3Gal4 gene deletion possibly 
related to effects on neuronal VGICs.  Preliminary studies were also performed on left 
ventricular epicardiums using optical mapping methods following isoproterenol treatment 
delivered through the perfusate.  Data from these experiments require analysis; however, 
a heightened effect on ST3Gal4
-/-
 ventricular epicardiums, similar to those observed 
through ECG recordings, may help determine the site of apparent potentiated action of 
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isoproterenol on the ST3Gal4
-/-
 mice.  Cellular studies may also be performed to ascertain 
if the effect in found at the myocyte level. 
 
 
Figure 3.20: A low dosage of isoproterenol significantly affects ST3Gal4
-/-
 
conduction with little to no effect on WT.  Results of ECG telemetry experiments on 
ST3Gal4
-/-
mice (top KO1 and middle KO2) and WT (bottom) following an 
intraperitoneal injection of isoproterenol (8mg/kg).  Marked changes in cardiac 
conduction were observed in both ST3Gal4
-/- 
mice suggesting a possible reduction in 
repolarization reserve consistent with the AP and IK data.  
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Chapter 4 
Discussion 
 
4.1. ST3Gal4 gene deletion directly alters Nav sialylation and gating and myocyte 
refractory period 
Here we demonstrate that deletion of the ST3Gal4 gene causes significant 
changes in ventricular Nav gating and activity, but does not impact Nav surface 
expression or maximal current density (Figs. 3.1 - 3.4 and 3.6).  Small, but uniform and 
significant shifts in the voltage-dependence of steady-state activation and inactivation 
gating were observed.  The shifts in gating, while uniform, will likely cause opposing 
effects on electrical excitability.  A rightward shift in Nav activation voltage will cause a 
loss-of-function because channels will require a greater depolarization to activate.  A 
missense mutation (R282H) in the human Nav1.5 gene (SCN5A) discovered in a family 
pedigree was linked to Brugada-like ECG characteristics including a coved and elevated 
ST segment and nocturnal syncope due to polymorphic ventricular tachycardia[280].  
Expression system studies of the mutated gene product showed a depolarizing shift in Va 
of ~5 mV similar to the shift observed in this study.  There are a number of other 
examples were congenital defects in SCN5A cause relatively small depolarizing shifts in 
Va[281-283].  These shifts, parallel to that observed from ST3Gal4
-/-
 mice Nav, may 
contribute to dangerous phenotypes consistent, in terms of ECG properties, with Brugada 
syndrome.  Conversely, a depolarizing shift in Vi would render fewer inactivated 
channels at a given membrane potential: a gain of Nav function, which was linked to 
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LQT3 and other isolated conduction diseases[284-288].  A rightward shift in both steady-
state events results in a depolarization of the window current, which may lead to 
increased excitability[70], and is also associated with LQT3[286, 289].  In agreement 
with a rightward shift in activation voltage, we observed a slowing of fast inactivation at 
hyperpolarized potentials.  Slower fast inactivation can manifest as a gain of Nav function 
and cause life-threatening arrhythmias[70, 289, 290].  Because the portion of the AP 
where “persistent” INa, originating from a slowing of fast inactivation, would be 
conducted is controlled by a delicate balance of ionic flux, only a marginal increase in 
current is necessary for arrhythmogenesis[290-292].  In fact, persistent current as little as 
1-5% of the maximum current can cause an extension of the AP that may lead to 
significant arrhythmias[291, 293].  Additionally, many SCN5A mutations demonstrate 
multiple phenotypes that are associated with both losses- and gains-in-function when 
studied in expression systems; concurrent with this, patients harboring these mutations 
can present with multiple ECG lesions[294-296].  These combinatory Nav phenotypes are 
similar to those which are described here for ST3Gal4
-/-
 Nav.  Thus, the influence of sialic 
acid on Nav gating and fast inactivation is confounding and may contribute opposing 
effects on myocyte excitability.  However, consistent with a rightward shift in activation 
and a slowing of fast inactivation, the data here describe a slowing of the time to AP peak 
and the time of maximum AP slope with no change in peak amplitude or maximum AP 
slope.  Additionally, the slowing of fast inactivation is a substrate for "persistent" INa that 
may contribute to the observed extension of APD particularly at 25 and 50% of 
repolarization (Figs. 3.4 and 3.17)[297].   
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Data from the biochemical experiments using sialidase A suggest that there are 
fewer sialic acid residues on Nav from ST3Gal4
-/-
 ventricles than are attached to Nav 
expressed in WT ventricles (Fig. 3.7).  Interestingly, while the depolarizing shifts in 
activation and inactivation described here were consistent with previous reports, the 
magnitudes of the shifts were smaller than those of other studies where shifts of 7-8 mV 
were observed[177, 178].  While both previous studies were performed using a different 
experimental system than was used here, one might still predict that, in the previous 
studies, the amount of (functional) sialic acid removed from Nav (using prolonged 
incubation with neuraminidase at an elevated temperature) or prevented from being 
attached to Nav (with the deletion of a polysialyltransferase gene) was greater than that 
observed here for the untreated ST3Gal4
-/-
 myocytes.  If so, then this could explain the 
smaller sialic acid dependent shift observed for ST3Gal4
-/-
 Nav gating.  The present 
model differs in that ST3Gal4 is only 1 of 20 sialyltransferases that adds a single sialic 
acid to a specific glycans; therefore it is reasonable to assume, based on this and the 
biochemical data, that ST3Gal4 is only one component in a complicated process whereby 
glycosylation contributes to electrical signaling.  This and the previous reports support 
the idea that sialylation affects Nav gating through a saturating mechanism; whereby, as 
the number of functional sialic acid residues increases so too does the hyperpolarizing 
effect on the channel’s voltage-dependent gating properties.  Additionally, together, and 
consistent with previously reported data[175-179, 184, 214], the biophysical data (Figs. 
3.2 - 3.4) for less sialylated Nav, combined with the biochemical data (Fig. 3.7), strongly 
suggest that at least some of the effects of ST3Gal4 gene deletion on Nav function are 
100 
 
likely mediated directly via a decrease in the number of functional sialic acids attached to 
Nav  subunits. 
An important contribution of Nav activity to cardiac conduction is the time needed 
for channels to recover from fast inactivation.  Recovery from fast inactivation is a 
voltage-dependent process involving the movement of the S4 region of domain IV[298, 
299] and therefore would likely be affected by a reduction in negatively charged SA 
residues from the external electric field.  Here we report that deletion of ST3Gal4 causes 
~23% increase in the rate of recovery from fast inactivation of Nav (Fig. 3.5).  A similar 
change in channel function was observed among a group of mutations in SCN5A[300].  
These mutations are well conserved within a number of familial cases of idiopathic 
ventricular fibrillation (IVF), which are associated with life-threatening heart rhythm 
disturbances[300].  In fact, the degree of increased recovery rate for ST3Gal4
-/-
 Nav 
observed here is more dramatic than that shown previously to be associated with IVF.  
SCN5A mutations that cause an acceleration in recovery from fast inactivation present a 
significant gain-in-function.  There are a number of these mutations that are associated 
with LQT3 and increase the rate of recovery from fast inactivation anywhere between 29 
to 65% of the WT channel in expression system studies, although some of these protocols 
were performed at different membrane potentials ranging from -120 to -90mV making 
them difficult to compare[286, 287, 301-303].  An acceleration in recovery from fast 
inactivation of Nav would likely have two major effects on the AP.  Because the 
probability of a channel reopening as the membrane repolarizes would be increased, an 
increase in recovery rate could extend the duration of the AP, which was observed in 
ST3Gal4
-/-
 ventricles (Fig. 3.17).  Additionally, an acceleration in recovery may decrease 
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the time needed for a second AP to fire, or the cellular refractory period.  To test whether 
the acceleration of Nav recovery from fast inactivation affects cellular conduction, we 
estimated the myocyte AP refractory period, finding that the refractory period is 
shortened by a significant ~21% in ST3Gal4
-/-
 myocytes, consistent in magnitude and in 
predicted impact, with the observed acceleration of recovery from fast inactivation for 
ST3Gal4
-/-
 Nav (Fig. 3.8). 
Based on the data presented here and in other studies investigating the effects of 
sialic acids on Nav activity, it seems that relatively modest changes in the external 
electrical field (although the exact magnitude is not known), which would likely occur 
following a reduction in sialic acids, significantly affects channel function.  This 
alteration in the external electric field likely influences the manner in which the channels 
gate leading to changes in function that mimic those caused by mutations in SCN5A that 
are associated with aberrant conduction.  It is interesting to note that, in humans, these 
marginal shifts in Nav function are associated with significant arrhythmias (although 
there is rarely a direct link demonstrated); however, there is no gross cardiac phenotype 
in the ST3Gal4
-/-
 mouse.  A likely explanation for this is that the mouse heart 
demonstrates little susceptibility to arrhythmia likely because of its rapid rate and lack of 
significant variability in rate[47].  The human heart rate, on the other hand, will display 
striking variability in rate based on stimuli and different physiological settings (sleep, 
exercise, etc.).  Many patients that suffer from Brugada syndrome, LQT or other 
conduction disorders associated with mutations in SCN5A often experience the most 
dramatic symptoms during sleep/relaxation, exercise or even fever when heart rate is 
altered or the body temperature is raised[280, 281, 283, 304-306].  In fact, in many cases 
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the ECG symptoms in humans are only revealed following exercise or pharmacological 
intervention[307-309].  These dynamic changes in heart rate likely occur less frequently 
in mice.  Therefore, under normal conditions, the observed differences in ST3Gal4
-/-
 Nav 
function likely do not contribute to significant alterations in cardiac excitability that 
would cause a gross phenotype including unexplained/sudden death or shortened life 
spans. 
 
4.2. Deletion of ST3Gal4
 
causes specific non-uniform effects on IK and KV expression 
 The data presented in this report indicate that deletion of ST3Gal4 has a 
significant impact on repolarizing K
+
 currents.  Peak IK density recorded from ST3Gal4
-/- 
myocytes was smaller at all test potentials compared to WT controls (Fig. 3.10).  
Dissection of the current into three kinetic components indicated a range of effects.  Ito 
and IKslow densities from ST3Gal4
-/-
 myocytes were smaller at less depolarized potentials 
than WT but similar at larger ones (Figs. 3.10B and C).  In agreement with the idea that 
this would likely be caused by depolarizing shifts in activation gating for each of the two 
kinetic current types, G-V relationships and Va were both depolarized for Ito and IKslow 
with no difference in maximal conductance density for ST3Gal4
-/-
 myocytes (Figs. 3.11 
and 3.12).  Western blotting of sarcolemmal enriched protein indicated similar expression 
for Kv4.2 and Kv1.5 protein.  There was a small but significant ~20% reduction in Kv2.1 
protein from ST3Gal4
-/-
 ventricular tissue.  ISS density was decreased at depolarized 
voltages (Fig. 3.16).  Following treatment of WT and ST3Gal4
-/-
 myocytes with 5 mM 
TEA (which blocks Kv2.1) no differences in ISS densities were detected suggesting that, 
while utilizing this methodology to delineate the different K
+
 current types, Kv2.1 may 
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contribute to ISS biophysically although likely not molecularly.  If the decrease in 
ST3Gal4
-/-
 Kv2.1 protein contributed to the reduction in ISS density how could deletion of 
the ST3Gal4 gene cause this?  There is evidence that the desialylation of glycan 
structures of ion channels affects surface retention and internalization by unmasking 
binding sights of carbohydrate binding proteins galectins[210, 213].  Additionally, 
neuraminidase treatment of isolated cardiac myocytes caused a reduction in IK 
density[194].  This is in contrast to results from this study and others investigating Nav 
activity following enzymatic desialylation or genetically mediated reductions in 
glycoprotein sialylation where there has been no reported effect on current density or 
surface expression.  Perhaps sialylation imparts an additional effect on Kv relating to 
trafficking and internalization of the proteins that differs from that of Nav.  Also unlike 
the effect of sialic acid on Nav were the non-uniform shifts in SSA and SSI.  While 
ST3Gal4
-/-
 Ito and IKslow demonstrated 8 and 7 mV shifts in Va and G-V relationships, 
respectively, compared to WT controls, voltage-dependent inactivation was not affected 
by ST3Gal4 gene deletion as evidenced by the lack of significant differences in SSI 
relationships and Vi between the two groups (Fig. 3.13 and Table 3.2).  These findings 
are consistent with previous reports in that sialic acid has a non-uniform effect on Kv 
gating where activation is effected but inactivation is not[195, 196].  This suggests a 
difference in the coupling between voltage-dependent activation and inactivation in Kv 
compared to Nav, which have consistently demonstrated uniforms shifts in both voltage-
dependent activation and inactivation following desialylation.  There is also evidence that 
sialic acids (or perhaps glycosylation in general) may affect Kv activity through 
mechanism that do not involve electrostatic interactions[310, 311].  The slopes of the 
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Boltzmann fits for Ito and IKslow activation were broadened in the ST3Gal4
-/-
 myocytes 
(Table 3.2).  A similar finding was made by Watanabe et al., as described in the 
introduction[310].  The grouped hypothesized that glycans confer an additional effect on 
channel gating likely caused by their influence on protein stability and the movement of 
domains during gating.  Also in support of this is the finding that the effect of ST3Gal4 
gene deletion on fast inactivation of IKslow did not demonstrate any appreciable voltage-
dependence suggesting perhaps a non-electrostatic mechanism (Fig. 3.14B).  Kv1.5, 
which putatively contributes to IKslow, inactivates through C-type inactivation, which is 
generally not considered voltage-dependent, although in native tissue an additional N-
type inactivation is conferred likely through the actions of the β subunit Kvβ1.3; however, 
this is typically only observed at near-physiological temperatures[268, 312].  Kv2.1 is 
also thought to contribute to IKlsow and has been described as having U-shaped 
inactivation, which is a novel type of channel inactivation that can be described as having 
multi-phasic responses to voltage, although the physiologic consequence of U-type 
inactivation is poorly understood[313].  A slowing of inactivation would likely contribute 
to longer K
+
 efflux and would confer a gain-in-function.   
Repeated attempts to compare the relative levels of sialylation on the various Kv 
isoforms from ST3Gal4
-/- 
and WT ventricular tissue were unsuccessful.  No appreciable 
shifts could be detected following enzymatic desialylation and western blotting, which 
was effective in comparing the extent of sialylation on Nav between the two groups.  This 
could be ascribed to the lack of sensitivity of the assay in detecting minor shifts in 
molecular weight and the fact that Kv are likely less glycosylated/sialylated compared to 
Nav.  Kv4.2 and Kv2.1 are only O-glycosylated and Kv1.5 has one putative N-linked 
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site[195, 196] compared to the 13 potential N-linked sites found on Nav1.5[175].  
Additionally, because Kv are tetramers, desialylation would affect the relative MW 1/4 as 
much as it would if they were one polypeptide as is the case with Nav.  It is interesting to 
note that while it appears as though the extent of glycosylation/sialylation is greater for 
Nav, the shifts in Va for Ito and IKslow were of greater magnitude.  One intriguing possible 
explanation for this is that the likely smaller glycan structures, particularly for O-linked 
Kv, may place the functional sialic acids in closer proximity to the voltage sensing 
machinery thereby exerting greater effects on gating.  Additionally, there is evidence that 
brain Kv isoforms have atypical internally linked sialic acids that would also likely be 
closer to the voltage-sensing portion of the channels than those terminally attached[189]. 
The observed effects of ST3Gal4 gene deletion on the activity of Kv in mouse 
.myocytes could have a significant effect on cellular and cardiac electrical excitability, 
which is supported by the AP, optical mapping and ECG data.  A rightward shift in 
activation gating with no effect on inactivation gating, which was observed for Ito and 
IKslow, would reduce the area of the window current.  Such a change could decrease the 
effective IK density.  A reduction of IK is the major contributor in LQT syndromes 1,2,5 
and 6[314].  While it is important to note that the Kv isoforms responsible for these 
diseases differ than those found in the mouse ventricle, the observed effects on the AP 
and ECGs should generally be conserved.  Additionally, both Kv1.5 and Kv2.1 are 
expressed in the human atria[315] indicating that diseases of glycosylation, which could 
affect the human isoforms in manners similar to those observed here, may have important 
ramifications on human atrial excitability or other tissues that express these channels.  
Kv1.5 is an important mediator in atrial fibrillation, which is the most common clinical 
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arrhythmia.  A down regulation of IK density and Kv1.5 protein expression were observed 
in patients with atrial fibrillation[315].  Subsequent studies have shown that congenital 
defects in the Kv1.5 gene cause losses-in-function that reduce current[316, 317].  An 
effective reduction in current, as described here originating from aberrant sialylation, 
could cause a similar pathology as that observed in patients with atrial fibrillation.  The 
predominate human ventricular Kv isoforms are Kv7.1 and Kv11.1[30, 42].  Kv7.1 (also 
referred to as KvLQT1) co-assembles with the auxiliary subunit minK to conduct the IKs 
current in the human ventricle.[318].  There are at least four mutations in the KvLQT1 
gene associated with LQT, Romano–Ward or Jervell and Lange–Nielsen syndromes, that 
demonstrate positive shifts in Va when studied in expression system, with three of the 
mutations requiring the co-expression of minK to demonstrate the observed shifts[319, 
320].  The functional result of these mutations is consistent with the effect of reduced 
protein sialylation on Kv reported here.  Gating of the KvLQT1-minK complex was also 
shown to be directly affected by protein glycosylation[321].  Expression in the Lec-1 
CHO cell line, which does not produce complex N-glycans and therefore cannot form N-
linked glycan structures that contain terminal sialic acids, shifted the Va by ~7mV 
compared to expression in the fully glycosylating Pro5 cell line, but only when both 
subunits were expressed.  While the authors were not investigating the effect of sialic 
acids directly, these data imply that KvLQT1 does not possess functional N-linked sialic 
acids but those found on the minK subunit can influence gating of the native channel 
complex.  Interestingly, when the pH was lowered, the Va of KvLQT1 expressed alone, in 
both cell lines, was depolarized suggesting that the channel may possess functional O-
linked sialic acids that were masked when the solution was acidified thereby shifting 
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gating as if sialic acids were removed.  However, these results do not rule out a direct 
effect of lower pH on channel gating.  More recently, a report described stark differences 
in the effect of deglycosylation on the minK subunit and the subsequent current produced 
by co-transfection with KvLQT1 than those previously mentioned[322].  The study 
described two N-linked glycosylation sites and one O-linked glycosylation site within the 
N-terminus of the minK subunit.  When mutants that lacked the various glycosylation 
sites were co-expressed with KvLQT1, no differences in Va were observed; however, 
there was a significant slowing of deactivation kinetics in both of the N-linked mutants.  
It is difficult to reconcile these two contrasting reports.  The only reasonable explanations 
are that the constructs used in the two studies differed in the number of glycosylation 
sites (the study using the glycosylation mutants focused on a discreet portion of the N-
terminus while the other study utilized CHO cell mutants that lack a glycogene that is 
necessary for the formation of sialic acid-linked N-glycans and did not mutate any 
potential glycosylation sites from minK or KvLQT1) or because of a difference in the 
manner in which the measurements were performed.  However, it is interesting to note 
that in the more recent study, where no effect on Va was observed, the authors described a 
co-dependence of glycosylation sites in producing the mature surface expressed KvLQT1-
minK complex.  When O-linked glycosylation was prevented through mutagenesis, all N-
linked glycosylation was blocked causing essentially none of the protein complex to 
reach the membrane surface.  Because glycosylation is a sequential process beginning in 
the ER and continuing throughout the Golgi, these results demonstrate that the concerted 
actions of many glycogene products are necessary for proper protein processing.  Defects 
in one step of the glycosylation process can have deleterious effects on others.  Improper 
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protein trafficking, via aberrant glycosylation, was linked to human arrhythmias or 
diseases of aberrant excitability that involve both minK/KvLQT1 and Kv11.1 (hERG-
product)[323-328].  These mutations cause a reduction in current density due to fewer 
channels at the surface, which then delays repolarization and extends the QT interval.  
Contrastingly, in a number of expression system studies, mutations that removed N-
linked glycosylation sites did not cause any appreciable differences in current densities, 
and therefore the likely surface expressions, of Kv1.4, Kv1.5, the drosophila shaker K
+
 
channel homolog as well as the hERG-product[191, 195, 250] although since the genetic 
material was not titrated, this may simply be an artifact of over-expression.  Additionally, 
sialic acids also have a hyperpolarizing effect on the gating of the hERG-product[250].  
However, because of the unique kinetics of the channel[329], it is likely that depolarizing 
shifts in gating following a reduction in functional sialic acids would cause a gain-in-
function and shorten the AP.  Modeling experiments utilizing the data have confirmed 
this and describe the shortening of the AP as well as a distortion of cardiac conduction 
following reductions in sialic acids in silico[330].   
How is it possible that myocytes from ST3Gal4
-/-
 mice demonstrate a decrease in 
peak IK density but the maximum conductance densities for Ito and IKslow are not different 
between the groups?  This is in stark contrast to the effect of ST3Gal4 gene deletion on 
INa where no change in maximum current density was observed and activation gating was 
depolarized.  As described earlier, one explanation is that the decrease in current densities 
of Ito and IKslow at smaller, non-saturating potentials (likely due to the positive shifts in the 
G-V relationships) and the decrease in ISS at saturating potentials, which may be related 
to the small but significant reduction in Kv2.1 protein, cause an overall reduction in 
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current at each test potential.  However, it is interesting to consider another possibility 
related to the inherent differences in the biophysical properties of Nav and Kv channels.  
Typically, Nav inactivate completely on the order of a few ms and the conductance is 
quickly saturated.  Contrastingly Kv inactivate more slowly and therefore an individual 
channel will “experience” a voltage during a pulse protocol or AP for a longer interval.  
During this interval, there is an equilibrium among individual channels between an open 
and closed state.  If channel gating is stochastic and the probability that a channel is open 
at a non-saturating voltage is decreased (as demonstrated by a rightward shift in the G-V 
relationship) then it is likely that fewer channels would be open within a population of 
similar channels compared to a population of channels where the G-V relationships are 
relatively hyperpolarized.  This along with a reduction in the area of the window current 
as described above would likely act to decrease the effective IK density, particularly over 
the voltage-range of a typical AP.  Regardless of the exact mechanism, functionally the 
data demonstrate this by the observed reduction in peak IK density/voltage relationships 
and the extension of the AP in ST3Gal4
-/-
 myocytes; although, the effects on the AP may 
also involve differences in Nav function.  In support of the idea that depolarizing shifts in 
gating may affect the effective current density of a Kv, previous reports have described a 
reversible electrostatic-mediated modulation of Kv gating by administration of positively 
or negatively charged fatty acid derivatives[331-333].  The impetus for these studies was 
based on the fact that polyunsaturated fatty acids have a beneficial effect on epilepsy and 
arrhythmias[334, 335].  In subsequent studies the authors incorporated some of the data 
into computer modeling experiments where they determined that a rightward shift of 5 
mV in Va can decrease the effective K
+ 
channel density as well as increase the chance of 
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repetitive AP firing both by 3 fold[332]; although, the model system was that of a 
myelinated frog axon where only one Nav and one Kv contribute to the AP.  In spite of 
this, these studies offer insight into the role of electrostatic-mediated effects of Kv gating 
and on cardiac electrical signaling.  Reported here are data consistent with these findings 
as described by the decrease in peak IK density and the extension of APD as well as the 
decrease in myocyte refractory period in ST3Gal4
-/-
 myocytes.  Typically, mutations in 
Kv genes that are associated with human diseases such as various LQT syndromes are 
associated with reductions in channel and current densities[336-339].  In addition to 
congenital diseases that reduce Kv surface expression thereby extending the AP, there are 
numerous examples of acquired pathologies that cause a reduction in IK and extend the 
AP[228, 340-342].  A reduction in Ito, which in humans is associated with reduced Kv4.3 
protein or the auxiliary protein KChiP, is often an important contributor to this process or 
is observed in disease models that attempt to investigate the mechanisms behind such a 
reduction[341, 343-345].  Much like an increase in “persistent” INa, a reduction in Ito 
affects the AP during a phase where only marginal changes in ionic flux can significantly 
increase the APD leading to an extension of the QT interval.  We observe here that 
deletion of the ST3Gal4 gene causes changes in IK that, functionally, mimic those 
associated with acquired and/or congenital diseases that cause Kv associated electrical 
remodeling without a significant change in Kv protein expression (other than the apparent 
20% reduction in Kv2.1 protein in ST3Gal4
-/-
 ventricular tissue) .  Moreover, the 
reduction in IK density, which likely, at least in part, contributed to the extension of APD, 
could lead to a reduction in repolarization reserve.  This is consistent with the ECG data 
following isoproterenol treatment whereas the ST3Gal4
-/-
 mice demonstrated a 
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significantly lower threshold for aberrant conduction following a cardiac “challenge.”  
Repolarization through Kv is considered an important mediator in the maintenance of 
repolarization reserve in humans[346-348]. 
 
4.3. ST3Gal4
 
is a substrate for arrhythmias 
If the reduction in myocyte refractory period, slowing of cellular conduction and 
the extension of APD are relevant to ventricular electrical signaling, one might predict 
that the ST3Gal4
-/-
 ventricle would be more susceptible to arrhythmias.  The optical 
mapping data show a significant 27% reduction in minimum refractory period and a clear 
increase in arrhythmic behavior in the ST3Gal4
-/-
 ventricle.  Arrhythmias were observed 
in nearly 75% of the ST3Gal4
-/-
 ventricles, with reentrant conduction, 
afterdepolarizations and/or ventricular fibrillation observed in >60% of the affected 
ventricles.  This susceptibility to arrhythmias is consistent with that predicted for a 
significantly reduced myocyte refractory period in which aberrant conduction would be 
expected to occur more frequently, potentially leading to ventricular fibrillation.  
Additionally, the differences in ST3Gal4
-/-
 myocyte AP waveforms, which may be 
attributed to both the changes in Nav and Kv function, could contribute to the reentry and 
afterdepolarizations observed in ST3Gal4
-/-
 ventricular epicardiums following 
stimulation.  Delayed repolarization is an important mediator in LQT syndromes where it 
is thought that the delay in repolarization can increase the heterogeneity of refractory 
periods among neighboring myocytes.  This dispersion in refractory periods can then lead 
to afterdepolarizations and the specific type of reentrant arrhythmia: torsade de pointes 
[60, 349].  In LQT3, an increase in APD can be associated with mutation in SCN5A that 
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demonstrate an increase in “persistent” INa, caused by the slowing of fast inactivation, and 
in an increase in the rate of recovery from fast inactivation[287, 301-303, 350].  More 
commonly, however, decreases in repolarizing K
+
 current associated with mutations in 
Kv genes are associated with the LQT phenotypes[42, 60, 71, 351-353].  Here, in 
myocytes from ST3Gal4
-/-
 mice, we see differences in Nav and Kv channel activity that 
parallel those of channel mutations associated with LQT syndromes.  Patients afflicted 
with the various LQT syndromes present with ECG lesions consistent with the 
arrhythmias observed in the optical mapping experiments following stimulation.  Based 
on the observed cellular data it is likely that the greater susceptibility to arrhythmias in 
the ST3Gal4 ventricular epicardium is due to some combinatory effect of aberrant Nav 
and Kv function.  Future optical mapping studies will be performed utilizing 
pharmacological approaches to block specific channel types in an attempt to discern if 
and how each channel type contributes to the observed arrhythmias.  Additionally, 
because reentrant arrhythmias associated with LQT-induced afterdepolarizations often 
involve Ca
2+
 influx due to reactivation of Cav before complete repolarization of the 
AP[349, 354], optical mapping approaches will also be used in future experiments to 
determine if differences in Ca
2+
 handling exist between WT and ST3Gal4
-/-
 ventricles.   
ECG recordings under basal conditions demonstrated only modest differences 
between groups.  Heart rates were slower in ST3Gal4
-/-
 mice, which is consistent with a 
slowing of cellular conduction and a loss-of-function in Nav, and demonstrated greater 
variability.  The duration of the P wave was extended in ST3Gal4
-/-
 ECGs suggesting an 
effect of atrial conduction.  Unpublished data from this lab demonstrated shifts in Kv 
gating and an extension of APD in ST3Gal4
-/-
 neonatal atrial myocytes compared to WT 
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controls.  Progressive cardiac conduction disease, which is characterized by a 
prolongation in conduction in the form of extended P, PR and QRS waveforms with no 
change in ST segment or QT interval, was associated with loss-in-function mutations in 
SCN5A that, when studied in expression systems, displayed phenotypes analogous to the 
positive shift in Va observed for ST3Gal4
-/-
 Nav[355-357].  No discernible differences in 
QT segments were detected between the two groups in contrast to the observed 
differences in cellular and epicardial electrical signaling observed in ST3Gal4
-/-
 
ventricular myocytes and ventricles.  One possible explanation may be related to the 
inherent and likely greater redundancy present in mouse cardiac 
conduction/repolarization compared to that found in human cardiac function as described 
in a previous section.  This redundancy could potentially mask aberrant conduction in the 
ST3Gal4
-/-
 mice.  As is often performed with humans to diagnose arrhythmias, ECG 
recordings of ST3Gal4
-/-
 and WT mice following administration of channel blockers will 
be performed in future experiments in order to attempt to uncover a more obvious 
pathological ECG phenotype in the ST3Gal4
-/-
 mice.  There was, however, a qualitatively 
observed increase in aberrant conduction in ST3Gal4
-/-
 mice ECGs, which was not 
observed in any WT mice, that included premature ventricular contractions, which is 
commonly associated with torsade de pointes[349].  It is also important to note that ECG 
parameters were difficult to measure, particularly QT segments, using these experimental 
conditions and latent differences may still exist.  Because the mice were ambulatory, 
there was a significant amount of noise associated with the telemetry recordings that 
decreased the ability of the software to identify and quantify the pertinent ECG 
parameters.  Studies are planned to perform surface ECGs on anaesthetized mice and on 
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Langendorff hearts.  Potentially, results from these studies will uncover differences in 
ventricular electrical signaling in the form of altered QT segments that are consistent with 
the cellular and epicardial data.  In spite of the lack of any significant ECG phenotype, it 
is interesting to consider the possibility that the alterations in Nav and Kv function, caused 
by ST3Gal4 gene deletion, may manifest as overlapping syndromes.  Under conditions of 
basal cardiac function, ST3Gal4
-/-
 ECGs are characterized by a slowing of conduction 
consistent with disorders that include progressive cardiac conduction disease or Brugada 
syndrome.  Following stimulation, however, ST3Gal4
-/-
 mice present with a distinct 
phenotype consistent with LQT as demonstrated by the optical mapping studies and the 
ECG recordings performed following administration of isoproterenol.  There are SCN5A 
mutations that are associated with similar overlapping phenotypes[295, 296, 358].  
Additionally, ECG patterns from ST3Gal4
-/-
 mice following isoproterenol treatment were 
consistent with those typically observed in patients with LQT syndromes and 
experiencing torsade de pointes or polymorphic ventricular tachycardia (Fig. 3.20).  
Diagnosis of LQT often requires administration of the non-specific adrenergic agonist 
epinephrine[359, 360].  These correlates suggest similarities between the effects of 
ST3Gal4 gene deletion on cardiac electrical signaling in the mouse and many human 
arrhythmias and therefore warrant additional studies.  
 
4.4. Could reduced Nav sialylation contribute to the altered excitability and 
conduction that present in glycosylation-associated diseases? 
Sialic acid affects Nav and Kv function through at least two mechanisms: 1) the 
glycosylation signature of each isoform dictates the magnitude of the sialic acid-mediated 
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effect[175, 176, 184] and 2) the cell-specific process of glycosylation affects Nav and Kv 
activities by changing the number of functional sialic acid residues on a given 
isoform[177-179]; for review see[249].  Here, we questioned how a single glycogene 
product that is uniformly expressed in the adult heart influences ventricular INa, IK and 
electrical signaling.  Previous reports demonstrated changes in Nav function and even cell 
excitability following desialylation; however, these studies typically removed SAs by 
treating the cells with enzymes that would remove all surface SA residues or by 
genetically ablating a specialized polysialyltransferase that is only expressed in the 
neonatal atria[177-179, 214].  Here we demonstrate that deletion of a glycogene product 
responsible for adding a single SA residue during the normal glycosylation process 
causes differences in channel function consistent with these previous reports.  The 
relatively modest differences appear to significantly affect ventricular excitability that 
does not result from a major change in protein trafficking or surface expression.  Because 
diseases such as CDG often result in reduced sialylation, we also set out to develop a 
model that would allow us to question whether such reduced sialylation could be partially 
responsible for the altered excitability often observed in these diseases.  Specifically, the 
mechanisms responsible for the observed symptoms that include hypotonia, 
developmental delay, seizures, and dilated or hypertrophic cardiomyopathies with related 
arrhythmias, are not yet understood.  Consistent with our findings here, nearly all CDG 
are associated with hypotonia[215], which may occur as a result of the observed 
rightward shift in Nav activation gating.  We also observed that a reduction in Nav 
sialylation can lead to gains-in-function that may contribute to the other more specific 
electrical maladies often observed in these patients including arrhythmias or 
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seizures[216, 217], although further experiments are necessary to confirm.  The effects of 
ST3Gal4 gene deletion on Kv function, which would generally be described as a loss-in-
function, are similarly consistent with the observed multi-system symptoms among CDG 
patients.  ECGs from CDG patients are often described as having elevated ST segments 
although, in many cases found in the literature, the ECG patterns are not adequately 
quantified and patients are simply described as demonstrating enigmatic arrhythmias[216, 
252, 361, 362].  It is likely that the effects of reduced glycosylation, caused by CDG, lead 
to overlapping phenotypes through an effect on multiple channel types.  This 
combination of effects is likely responsible for the seemingly disparate clinical symptoms 
that include hypotonia as well as seizures and arrhythmias. 
 Chagas disease is caused by the single-celled eukaryotic parasite Trypanasoma 
cruzi that infects the heart and affects 16-18 million people in the Americas alone[221].  
The organism produces a trans-sialidase that was shown to remove sialic acids from 
mammalian cells[218, 253].  Chagas disease is associated with severe pathological 
changes in ECGs that include atrial fibrillation, ventricular tachycardia, premature 
ventricular contractions as well as various types of conduction block[363, 364]  While 
many ascribe the effect to the development of fibrosis and/or hypertrophy, conduction 
anomalies are more prevalent in those with Chagas disease than in those with other forms 
of dilated cardiomyopathy[221].  Additionally, mice infected with two distinct strains of 
T.cruzi showed altered ECGs prior to the development of fibrosis or wall thickening 
implicating a second mechanism that may involve the desialylation of 
glycoproteins[220].  There are other examples of acquired pathologies that may affect 
glycosylation indirectly, which then may contribute to the disease symptoms.  The 
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muscle LIM protein KO mouse (MLP
-/-
)
 
is an established and reproducible model for 
human heart failure[365-368].  In a 2001 study, Ufret-Vincenty et al. utilized the MLP
-/-
 
strain to assess how induced heart failure, by MLP gene deletion, affected cardiac 
conduction and ventricular APs and Nav function.  ECGs of sedated mice indicated a 
number of conduction abnormalities in the MLP
-/-
 hearts compared to controls including 
an approximate 88% increase in QT interval.  Current-clamp recordings of isolated 
ventricular myocytes from MLP
-/-
 mice demonstrated a significant increase in APD90.  
Additionally, rapid AP induction caused increased susceptibility to EADs in the MLP
-/-
 
ventricular myocytes.  INa recorded from MLP
-/-
 mice was characterized by a decrease in 
maximal current density and shifts in gating consistent with those described here.  
Western blot analysis showed a decrease in MLP
-/-
 mouse Nav band intensity as well as a 
narrowing of band width and an apparent decrease in molecular weight of the protein 
isolated from the MLP
-/-
 strain.  Based on these data, the group hypothesized that the Nav 
protein from the MLP
-/-
 was aberrantly processed and likely was less glycosylated.  To 
test this, ventricular myocytes from both groups were treated with neuraminidase.  
Compared to untreated control cells, INa from control myocytes treated with 
neuraminidase was characterized by similar shifts in gating to those observed in the 
untreated and neuraminidase-treated MLP
-/-
 cells and cells from ST3Gal4
-/-
 ventricles.  
The study suggested that an acquired change in sialylation, in this case mediated through 
a model of heart failure, can impact cardiac excitability.  In another study, using an 
animal model of ventricular tachycardia that led to heart failure, rapid pacing of canine 
hearts caused changes to the glycosylation profile of the Ca
2+ 
handling protein 
calsequestrin[224].  These examples demonstrate how changes in 
118 
 
glycosylation/sialylation may contribute to the onset and development of cardiac disease.  
The current dogma dictates that, through remodeling, VGICs contribute to 
cardiomyopathies and arrhythmias.  However, it is apparent based on these examples and 
others that glycosylation can be similarly altered through disease or through normal 
development and/or vary among different cell/tissue types.  Sialic acid affects Nav and Kv 
function; therefore it seems reasonable to assume that through changes in the 
glycosylation/sialylation of Nav and Kv that it too may contribute to pathological 
electrical remodeling.  The data presented in this and other studies highlights the potential 
contribution of protein glycosylation in cardiomyopathies and introduces it as a novel and 
new paradigm that warrants attention when investigating disease that affect cardiac 
excitability.  
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Chapter 5 
Summary 
 
The mouse heart is resistant to arrhythmogenic activity and typically requires 
considerable genetic perturbations to manifest significant changes in cardiac conduction 
and/or repolarization[47].  Nonetheless, we see here that deletion of a single 
sialyltransferase that is uniformly expressed throughout the heart can cause differences in 
Nav and Kv function that likely contribute to the differences in cardiac electrical signaling 
observed in ST3Gal4
-/-
 mice.  Many of these differences mirror those caused by a number 
of congenital defects in cardiac Nav and Kv responsible for such human diseases as LQT 
and Brugada syndrome[70, 369, 370].  Among the changes in Nav function, we observed 
a significant increase in the rate of Nav recovery from fast inactivation that is likely 
responsible, at least in part, for the observed decreased cellular and ventricular refractory 
periods.  Additionally, the rightward shift in Va of Nav from ST3Gal4
-/- 
myocytes would 
be expected to contribute to a slowing of cellular conduction as observed by the increase 
in time to AP peak, which may be pro-arrhythmogenic.  The observed differences in Kv 
function likely result in an effective reduction in channel density and repolarization 
reserve as evidenced by the increase in APD and ECG recordings following isoproterenol 
treatment.  Changes in AP waveform, particularly an increase in duration, are a hallmark 
of numerous cardiac pathologies that lead to life-threatening arrhythmias.  Consistent 
with a decreased refractory period and extension of APD is the pro-arrhythmogenic 
behavior of the ST3Gal4
-/-
 left ventricular epicardium.  Thus, the data presented in this 
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study describe a potential novel mechanism by which reduced sialylation may contribute 
to the increased susceptibility to arrhythmias observed in individuals with several forms 
of CDG and in those afflicted with Chagas disease.  Additionally, the data further 
elucidate the role of sialylation in normal cardiac electrical signaling. 
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Chapter 6 
Future Studies 
 
 The ST3Gal4 mouse is likely only a modest representation of glycosylation-
associated diseases.  In spite of this, the model presents a significant phenotype that 
offers insight into the effect of such diseases on cardiac excitability.  Future studies will 
no doubt attempt to more accurately represent human diseases of glycosylation.  For 
example, there are a number of mouse models of Chagas disease that may be useful in 
similar studies.  Additionally, mutated glycogenes that contribute particularly strong 
cardiac phenotypes among different CDG can be targeted in other transgenic mouse 
studies.  Overall, the biophysical properties of VGICs are often overlooked when 
designing strategies to intervene in diseases that relate to electrical excitability.  These 
studies, while focused on glycosylation, describe how likely alterations in the external 
surface potential of a cell may modulate channel activity as well as cell and tissue 
excitability.  Changes in VGIC function (gains- or losses-in-function) are pro-
arrhythmogenic and contribute to congenital diseases such as Brugada syndrome and 
LQT as well as acquired diseases that include heart failure and hypertrophy[72, 228, 370-
374].  Specific targeting of ion channels, such as Nav1.5 or Kv11.1, by highly specific 
antibodies or attenuated toxins that are derivatized with charged functional groups may 
offer a useful means to “tune” electrical excitability.  These strategies would offer a 
highly specific treatment for many of these diseases, where current techniques often lead 
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to unwanted effects on other channel types.  Studies investigating the efficacy of such 
strategies warrant further investigation.   
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